OPEN ACCESS

University of Dundee

University of Dundee

Regulation of AMP-activated protein kinase by natural and synthetic activators

Grahame Hardie, David

Published in:
Acta Pharmaceutica Sinica B

DOI:
10.1016/j.apsb.2015.06.002

Publication date:
2016

Licence:
CC BY-NC-ND

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Discovery Research Portal

Citation for published version (APA):
Grahame Hardie, D. (2016). Regulation of AMP-activated protein kinase by natural and synthetic activators. *Acta Pharmaceutica Sinica B*, *6*(1), 1-19. https://doi.org/10.1016/j.apsb.2015.06.002

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 05. May. 2023

Acta Pharmaceutica Sinica B 2016;6(1):1–19

Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



REVIEW

Regulation of AMP-activated protein kinase by natural and synthetic activators

David Grahame Hardie*

Division of Cell Signaling & Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK

Received 27 April 2015; accepted 28 May 2015

KEY WORDS

AMP-activated protein; kinase;
Energy balance;
AMP;
AMPK activator;
Mitochondrial function;
Regulatory mechanism

Abstract The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status that is almost universally expressed in eukaryotic cells. While it appears to have evolved in single-celled eukaryotes to regulate energy balance in a cell-autonomous manner, during the evolution of multicellular animals its role has become adapted so that it also regulates energy balance at the whole body level, by responding to hormones that act primarily on the hypothalamus. AMPK monitors energy balance at the cellular level by sensing the ratios of AMP/ATP and ADP/ATP, and recent structural analyses of the AMPK heterotrimer that have provided insight into the complex mechanisms for these effects will be discussed. Given the central importance of energy balance in diseases that are major causes of morbidity or death in humans, such as type 2 diabetes, cancer and inflammatory disorders, there has been a major drive to develop pharmacological activators of AMPK. Many such activators have been described, and the various mechanisms by which these activate AMPK will be discussed. A particularly large class of AMPK activators are natural products of plants derived from traditional herbal medicines. While the mechanism by which most of these activate AMPK has not yet been addressed, I will argue that many of them may be defensive compounds produced by plants to deter infection by pathogens or grazing by insects or herbivores, and that many of them will turn out to be inhibitors of mitochondrial function.

© 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

*Tel.: +44 1382 384253.
E-mail address: d.g.hardie@dundee.ac.uk

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

http://dx.doi.org/10.1016/j.apsb.2015.06.002
2211-3835 © 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The 5'-adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a sensor of cellular energy that helps to maintain energy balance at both the cellular and whole body levels[1–4]. Since type 2 diabetes, which affects 5% − 10% of the world population, can be regarded as a disorder of energy balance caused by over-nutrition, there has been much interest in AMPK as a drug target. It is also becoming apparent that two other major causes of human death and morbidity, *i.e.*, cancer and inflammatory disease, can be viewed as metabolic derangements. Thus, tumor cells and cells, involved in inflammation, tend to display a glycolytic phenotype (termed the Warburg effect or aerobic glycolysis), whereas quiescent cells and cells involved in the resolution of inflammatory responses tend to utilize oxidative metabolism[5]. Since AMPK inhibits cell growth and proliferation, and also promotes the more glucose-sparing and energy-efficient mitochondrial oxidative metabolism rather than glycolysis, interest in the system as a drug target in the fields of cancer and inflammatory disease has been steadily increasing.

Following its initial definition by our group in the late 1980s[6–8], over 9000 papers have been published on the AMPK system, and it is not possible to give a full coverage of the field in a single article. In this review I will focus on its structure and evolution, its regulation by metabolites, and its modulation by synthetic compounds that are being developed as pharmacological AMPK activators and by natural products that are being tested as medicines.

2. AMPK—subunit structure and evolution

AMPK appears to exist in almost all eukaryotic species as heterotrimeric complexes comprising a catalytic α subunit and regulatory β and γ subunits. In humans and other mammals, the α subunits are encoded by two genes (*PRKAA1*/*PRKAA2*, encoding $\alpha1/\alpha2$), the β subunits by two (*PRKAB1*/*PRKAB2*, encoding $\beta1/\beta2$) and the γ subunits by three (*PRKAG1*/*PRKAG2*/*PRKAG3*, encoding $\gamma1/\gamma2/\gamma3$). All twelve combinations of α, β and γ subunit isoforms are able to form heterotrimeric complexes when co-expressed, although certain combinations appear to be favored *in vivo*[9]. Genes encoding orthologs of AMPK-α, -β and -γ subunits are readily found in all eukaryotes where genome sequences have been completed. The one known exception to this is the microsporidian *Encephalitozoon cuniculi*, an obligate intracellular parasite that lives inside other mammalian cells including those of humans, and which has no free-living form other than metabolically inert spores[10]. While a genuine eukaryote, *E. cuniculi* has an extremely small genome encoding only 29 conventional protein kinase catalytic subunits, and lacks genes encoding the α, β and γ subunits of AMPK[11]. It does contain genes encoding the enzymes required for a complete glycolytic pathway[10], but lacks adenosine-triphosphate (ATP)-generating mitochondria although having mitochondrial remnants termed mitosomes[12]. Interestingly, *E. cuniculi* expresses unusual transmembrane ATP/adenosine diphosphate (ADP) translocases, some of which appear to be located in the plasma membrane[13]. The implication of this is that the organism may utilize these translocases to "steal" ATP from the host cell in exchange for ADP. *E. cuniculi* may therefore have been able to afford to lose genes encoding AMPK, because its host cell does express the kinase and can regulate energy homeostasis on its behalf.

Given that AMPK is found in essentially all present day eukaryotes, it seems likely that it evolved soon after the development of the first eukaryote. It is widely believed that the key event that led to the first eukaryotic cell was the endosymbiotic acquisition by an archaeal host cell of aerobic bacteria, which eventually became mitochondria. One can speculate that the host cell would have needed a system to monitor the output of their newly acquired oxidative organelles, and to regulate the ability of those organelles to supply ATP according to the demands of the host. AMPK fits the bill to be such a system: for example, in the budding yeast *Saccharomyces cerevisiae* the AMPK ortholog is not required for growth by the fermentative metabolism (*i.e.*, glycolysis) that is utilized in high glucose, but is required for the switch to oxidative metabolism that occurs when glucose run low[14]. Similarly, mitochondrial biogenesis is one of the key downstream effects of AMPK activation in mammalian cells[15–17].

Most energy-requiring processes in eukaryotic cells are driven, either directly or indirectly, by hydrolysis of ATP to ADP, and it is possible to draw an analogy between these nucleotides and the chemicals in a rechargeable battery. A high ratio of ATP to ADP is equivalent to a fully charged battery, while if this ratio is falling the cellular battery is becoming flat. Extending this analogy, AMPK can be regarded as the biological equivalent of the system within a cell-phone or laptop computer that monitors the battery charge. As discussed in more detail in Section 3, it is activated by increasing ratios of AMP/ATP and ADP/ATP. An increase in either ratio signifies falling cellular energy, but if the reversible reaction catalyzed by adenylate kinase ($2ADP \leftrightarrow ATP + AMP$) is at equilibrium (as seems to be the case in most eukaryotic cells) it is easy to show that the AMP/ATP ratio will vary as the square of the ADP/ATP ratio[18], making the former a much more sensitive signal of falling energy status than the latter. A full description of the downstream targets for AMPK is beyond the scope of this article, and readers interested in that aspect should consult other reviews (*e.g.*, Ref. 19). However, once activated by energy stress, AMPK attempts to restore cellular energy homeostasis by activating catabolic pathways that generate ATP, while switching off ATP-consuming processes not essential to short-term cell survival, including almost all anabolic pathways. Although AMPK almost certainly arose in single-celled eukaryotes as a cell-autonomous mediator of energy balance, it is intriguing that role of the system seems to have become adapted during the evolution of multicellular eukaryotes so that it also regulates energy balance at the whole body level. It does this particularly by mediating effects of hormones acting on the hypothalamus of the brain that control energy intake (*i.e.*, feeding) and energy expenditure[1–4].

3. Canonical regulation by phosphorylation and by adenine nucleotides

AMPK is normally only significantly active after phosphorylation of a conserved threonine residue within the activation loop of the kinase domain on the α subunit. This threonine residue is usually referred to as Thr172 due to its position in the rat $\alpha2$ subunit where originally identified[20], although the precise numbering may differ in other isoforms and species. Following a long search, the primary upstream kinase that phosphorylates Thr172 *in vivo* was shown to be a heterotrimeric complex between the tumor suppressor kinase liver kinase B1 (LKB1), the pseudokinase STE20-related adaptor (STRAD) and the scaffold protein mouse protein 25 (MO25)[21–23]. This complex appears to be constitutively active in that its activity is not regulated under situations of energy stress when AMPK is activated in an LKB1-dependent manner[24,25]. Nevertheless, binding of AMP to AMPK can regulate both the phosphorylation of Thr172 by LKB1, and its

dephosphorylation (see below). Almost as soon as it was found that LKB1 was the primary upstream kinase, it was realized that there was some phosphorylation of Thr172 even in tumor cells that had lost LKB1, and this was traced to the calmodulin-dependent protein kinase, calcium/calmodulin-dependent protein kinase kinase β (CaMKKβ)[26–28]. This provides an alternate Ca^{2+}-mediated upstream pathway for AMPK activation, which mediates effects of hormones and mediators acting through G_q/G_{11}-coupled receptors that trigger release of Ca^{2+} from intracellular stores *via* the second messenger inositol-1,4,5-trisphosphate (IP_3)[29]. Such hormones include thrombin acting on endothelial cells *via* the protease-activated receptor[30], and ghrelin acting on hypothalamic neurons *via* the glutathione reductase 1 (GSHR1) receptor[31]. Thr172 can also be phosphorylated, and AMPK activated, in intact cells by the protein kinase transforming growth factor-β-activated kinase-1 (TAK1)[32,33], although the physiological relevance of that mechanism currently remains unclear.

Allosteric activation of the phosphorylated kinase by 5′-AMP was originally demonstrated in 1980[34] (before AMPK acquired its current name), but in the early 1990s it was shown that AMP binding to AMPK not only caused allosteric activation but also promoted its net phosphorylation at Thr172[35]. It is now clear that AMP binding has three effects on AMPK[36] that activate the system in a synergistic manner, making the final response very sensitive to even small changes in AMP:

(i) promotion of phosphorylation by LKB1, but not CaMKKβ (although this selectivity for LKB1 has been disputed[37]);
(ii) protection against dephosphorylation of Thr172 by protein phosphatases; and
(iii) allosteric activation of the phosphorylated kinase.

Of these three effects, it has been reported that mechanisms (i)[37] and (ii)[38] are also mimicked by binding of ADP. Given that ADP is present in unstressed cells at concentrations ten times higher than AMP, and that allosteric activation (which is only caused by AMP binding) is often reported as being small in magnitude (<2-fold), this led to proposals that ADP rather than AMP might be the crucial activator of AMPK[37–39]. However, our group[36] reported that while mechanism (ii) can indeed be caused by binding of ADP, AMP is about 10-fold more potent. Moreover, using a native preparation of mammalian AMPK rather than a bacterially expressed complex, allosteric activation by AMP can be substantial (>10-fold), even in the presence of concentrations of ATP that are 1−2 orders of magnitude higher and within the physiological range (5 mmol/L)[36]. Thus, while ADP may contribute to activation, we would argue that AMP remains the primary regulator of AMPK.

4. Pharmacological activators of AMPK

Since the realization in the late 1990s that activation of AMPK might be useful for treatment of type 2 diabetes[40], numerous pharmacological activators have been developed. Based on their mechanism of action, they can be divided into four classes that are discussed in Sections 4.1–4.4.

4.1. *Activators that act indirectly by inhibiting cellular ATP synthesis*

Since depletion of ATP always causes increases in AMP and ADP, AMPK is activated by any compound that inhibits ATP synthesis. In cells that are primarily using glycolysis to generate ATP (as in most rapidly proliferating cells), AMPK is activated by inhibitors of glycolysis such as 2-deoxyglucose[41]. A much larger class of activators, some of which are shown in Fig. 1A, are those that inhibit mitochondrial ATP synthesis by inhibiting the respiratory chain at Complex I (*e.g.*, metformin or phenformin[42,43]) or Complex III (*e.g.*, antimycin A[44]), or that inhibit Complex V, the mitochondrial F1 ATP synthase (*e.g.*, oligomycin or resveratrol[41,45]). All of these agents will increase cellular ADP/ATP and/or AMP/ATP ratios, although correlations between such ratios and changes in AMPK activity do not prove on their own that activation by AMP or ADP is the sole mechanism. The best method to confirm this is to use a cell line expressing an AMP/ADP-insensitive mutant of AMPK such as the R531G mutation in $\gamma 2$[41] or the equivalent R299G mutation in $\gamma 1$[46]. Any agent that activates AMPK solely by increasing the cellular levels of AMP or ADP will fail to activate such mutants. Further discrimination can be obtained by measuring cellular oxygen uptake and acidification of the medium using an extracellular flux analyzer. Compounds that inhibit mitochondrial function should inhibit oxygen uptake, while those that inhibit glycolysis should reduce lactate output and hence extracellular acidification. For example, the compound PT-1, which was originally proposed to act by direct binding to AMPK[47], was recently shown using these methods to act instead by inhibiting the respiratory chain[46].

In the last few years well over 100 natural products or extracts derived from plants, many of which are used in traditional Asian medicines, have been reported to activate AMPK. These are considered in more detail in Section 7. However, it is worth stating here that several of them, including berberine[41,48] and arctigenin[49], appear to activate AMPK by inhibiting the mitochondrial respiratory chain, as does galegine, a natural product from the medicinal plant *Galega officinalis* from which metformin and phenformin were derived[41,50] (Fig. 1A). At least one potent synthetic compound, derived from a high-throughput screen designed to detect compounds that activate AMPK in cell-based assays, has also been shown to activate AMPK by inhibiting Complex I of the respiratory chain[51].

4.2. *Pro-drugs that are converted into AMP analogs inside cells*

It is clear that the regulatory adenine nucleotide-binding sites on the γ subunits of AMPK, which are discussed in more detail below, require the presence of negatively charged phosphate groups on bound nucleotides, and it therefore may be difficult to develop cell-permeable AMP analogs that bind these sites. However, a related approach is to develop pro-drugs that are cell permeable but are converted following their uptake into AMP analogs by cellular enzymes. In fact, 5-aminoimidazole-4-carboxamide ribonucleoside, the first pharmacological AMPK activator to be developed[49,50], works by this mechanism. This compound is often referred to as AICAR and I adopt this usage below, although this can cause confusion because researchers in the field of nucleotide metabolism use the same acronym to describe the phosphorylated ribotide form, which I will refer to instead as ZMP (AICAR monophosphate). AICAR is an adenosine analog that is taken up into cells by adenosine transporters[52] and phosphorylated by intracellular adenosine kinase into ZMP (Fig. 1B). ZMP is an AMP analog that binds to AMPK at the same sites as AMP[53] and mimics all of the effects of AMP on the



Figure 1 Structures of AMPK-activating compounds that act *via*: (A) inhibiting mitochondrial ATP synthesis; (B) pro-drugs converted to active agents inside cells, as shown; and (C) direct activators. (D) shows the mechanism by which antifolate drugs activate AMPK by causing accumulation of ZMP, an intermediate in the synthesis of the purine nucleotides inosine monophosphate (IMP), AMP and guanosine monophosphate (GMP).

AMPK system[54]. In fact, ZMP has low potency compared with AMP[54], but AICAR nevertheless activates AMPK in most primary cells and tissues because AICAR is rapidly converted to ZMP, which is then metabolized much more slowly. ZMP therefore accumulates within many cells to concentrations within the millimolar range (even higher than the external AICAR concentration), which is necessary for it to activate AMPK. It is important to note that ZMP is a natural intermediate in purine nucleotide synthesis, and some immortalized cell lines have a high rate of purine synthesis such that ZMP does not accumulate in response to extracellular AICAR, and AMPK is therefore not activated. Interestingly, however, antifolate drugs that are used to treat cancer, or inflammatory disorders such as rheumatoid arthritis, inhibit the transformylase that catalyzes the first step in the metabolism of ZMP to purine nucleotides, thus causing accumulation of ZMP (Fig. 1D). For example, the antifolate methotrexate dramatically sensitizes cells to the activating effects of AICAR[55], while pemetrexed can activate AMPK even in the absence of exogenous AICAR[56].

Recently, a synthetic compound that activates AMPK by a pro-drug mechanism has been developed. C13 is a phosphonate diester that is taken up into cells and converted by cellular esterases into C2 (Fig. 1B), an AMP analog that is 2−3 orders of magnitude more potent as an allosteric activator of AMPK than AMP, and 4 orders of magnitude more potent than ZMP[57]. Another major advantage of C13 over AICAR is that C2, unlike ZMP, does not modulate other AMP-sensitive enzymes such as glycogen phosphorylase, phosphofructokinase or fructose-1,6-bisphosphatase[58]. C2 is, however, selective for AMPK complexes containing the α1 rather than the α2 isoform[58], an interesting finding that is considered in more detail in Section 5.3 below. Finally, 3'-deoxyadenosine (cordycepin) is a bioactive compound derived from the fungus *Cordyceps militaris,* which is an analog of adenosine lacking oxygen on the 3' position of the ribose ring. Although it has been shown to activate AMPK in intact cells and to bind directly to the AMPK-γ subunit[59,60], it is perhaps more likely that the true activator is cordycepin-5'-monophosphate generated from cordycepin within the cell.

4.3. *Allosteric activators that bind directly to AMPK at sites distinct from the AMP sites*

The first compound in this class was A-769662 (Fig. 1C), developed by Abbott laboratories from a high throughput screen searching for allosteric activators of purified AMPK. Although it has poor oral availability, when administered by intraperitoneal injection it was found to have favorable effects on the metabolism of an insulin-resistant animal model, the *ob/ob* mouse[61]. A-769662 did not increase cellular ADP/ATP or AMP/ATP ratios[61], still activated AMPK in cells expressing an AMP-insensitive mutant[41], and did not displace AMP from its binding sites on the γ subunit[62], suggesting that it bound at a different site from AMP even though, like AMP, it caused both allosteric activation and protection against Thr172 dephosphorylation[62,63]. A-769662 is also selective for activation of β1 rather than β2 complexes[64], and its effects are abolished by an S108A mutation in β1 that prevents the autophosphorylation of that serine residue[63], suggesting that the binding site involved the β subunit. As discussed in Section 5.2 below, the binding site has now been identified by

structural biology to be a cleft located between the N-lobe of the kinase domain on the α subunit and the carbohydrate-binding module on the β-subunit. Another, more potent activator that binds at this site, 991[65] (also known as ex229[66]), has emerged from high-throughput screens (Fig. 1C). Like A-769662, this compound shows some selectivity for β1 complexes although it will activate β2 complexes at higher concentrations. A third compound, MT 63-78[67] (Fig. 1C), also shows selectivity for β1 complexes and may therefore bind this site, although this has not yet been formally demonstrated. None of these compounds has yet entered clinical trials. However, it should be noted that, of these compounds, only A-769662 has been available for a prolonged period, and enthusiasm for its entry into clinical trials may have been dampened in part by poor oral availability[61] and in part by the occurrence of AMPK-independent, "off-target" effects[68].

A key question regarding the binding site for A-769662 is whether it binds any naturally occurring ligands. One natural product derived from plants that does bind to this site is salicylate[69], which has been used as a medicinal compound by humans since ancient times[70]. Acetyl salicylic acid (ASA or aspirin), which is broken down to salicylate within minutes of its adsorption into the bloodstream, is a synthetic derivative developed in the 1890s as a less irritating formulation to deliver salicylate orally. Aspirin is a potent inhibitor of the cyclo-oxygenases[71] (COX1 and COX2) that catalyze the key initial steps in the biosynthesis of prostaglandins and other eicosanoids; irreversible inhibition of synthesis of the eicosanoid thromboxane A2 in platelets is the mechanism by which it inhibits platelet aggregation and hence blood clotting[72]. However, since aspirin and salicylate have equal potency as anti-inflammatory agents, yet salicylate is a very poor COX inhibitor, it remains unclear whether all of the anti-inflammatory actions of aspirin can be attributed to COX inhibition[73]. In 2012 we reported that salicylate, but not aspirin, activated AMPK[69]. Like A-769662, salicylate is a poor activator of β2 complexes and its effect were abolished by an S108A mutation in β1, so it seemed likely that it bound to the same site as A-769662[69], a proposal recently confirmed by a crystal structure of the human $\alpha1\beta1\gamma1$ complex with bound iodosalicylate[74]. When salicylate or A-769662 were injected into wild type mice, they promoted a more rapid switch from carbohydrate to fat oxidation on food withdrawal, as would be expected for an AMPK activator that triggered phosphorylation and inactivation of both isoforms of acetyl-CoA carboxylase (ACC1 and ACC2) and hence caused a rapid switch from fat synthesis to fat oxidation. However, these effects were lost in AMPK-β1 knockout mice; since salicylate and A-769662 do not activate β2-containing complexes, this provided strong evidence that these metabolic effects were mediated by AMPK[69].

When AMP and A-769662 are added to AMPK together, they cause a synergistic allosteric activation even of "naïve" AMPK complexes that are not phosphorylated on Thr172, although prior autophosphorylation of Ser108 (or a phosphomimetic S108E mutation) is required for a maximal effect, as well as for a maximal response to A-769662 alone[75]. Synergism between these activating sites may also be relevant in intact cells, because metformin (which increases cellular AMP) and salicylate act synergistically to activate AMPK and inhibit fat synthesis in isolated mouse and human hepatocytes—while little AMPK activation was observed with metformin or salicylate on their own at concentrations (100 μmol/L and 300 − 500 μmol/L, respectively) observed in human plasma following normal doses, significant effects were observed when they were given together[69]. There were also additive effects of low doses of metformin and salicylate *in vivo* to activate AMPK in livers of high-fat fed mice, accompanied by reduced liver triglycerides and increased hepatic insulin sensitivity[69].

4.4. *Oxidative stress*

It was reported in 2001 that oxidative stress produced by hydrogen peroxide increased Thr172 phosphorylation and activated AMPK; this was accompanied by increases in AMP/ATP ratios, suggesting that the effect might be AMP-dependent (*i.e.*, the mechanism described in Section 4.1)[76]. More recently, Zmijewski et al.[77] used glucose oxidase to generate H_2O_2 from glucose present in the medium—this appears to be a better model for physiological oxidative stress, because it generates a constant low level of H_2O_2 in the medium (<20 μmol/L) rather than a transient spike of much higher concentrations that is obtained by adding H_2O_2 directly[78]. Zmijewski et al. reported that glucose oxidase treatment of HEK-293 cells did not cause decreases in ATP levels, and presented evidence that AMPK activation was caused instead by oxidation of two conserved cysteine residues (Cys299 and Cys304) present in the auto-inhibitory domain of the α subunit (see Section 5.1). However, our group[78] reported that glucose oxidase treatment did increase AMP/ATP ratios in the same cell line, and that AMPK activation was largely abolished in HEK-293 cells expressing the AMP-insensitive R531G mutant of γ2. While this suggested that the effect was primarily AMP-dependent, there was a small residual effect observed with the R531G mutant that might be explained by the mechanism described by Zmijewski et al.[77]. More recently, Shao et al.[79] reported that AMPK was inactivated rather than activated by oxidative stress in primary cardiomyocytes, and that this was prevented by thioredoxin. Inactivation was traced to oxidation of two cysteine residues within the kinase domain of AMPK (Cys130 and Cys174), distinct from those whose oxidation was proposed by Zmijewski et al.[77] to cause activation of AMPK. Cys174 is almost adjacent to Thr172, and unmodified cysteine residues at these positions were shown to be necessary for activation by LKB1. Shao et al.[79] suggested that the activation of AMPK caused by oxidative stress in HEK-293 cells[77,78] may occur because higher levels of anti-oxidant enzymes in this immortalized cell line may prevent the inactivation that they observed in primary cardiomyocytes.

4.5. *Why do different pharmacological activators of AMPK have different effects?*

Some of the pharmacological activators of AMPK discussed above have been used as medicines by humans for decades (metformin), centuries (berberine) or even millennia (salicylate). Why are their pharmacological effects so different? One potential explanation is pharmacokinetics—for example, metformin is a cation with poor cell permeability, and it requires expression of transporters of the organic cation transporter (OCT) family, such as OCT1, for cellular uptake. Because OCT1 is highly expressed in hepatocytes, 24% of an intravenous dose of metformin was found in the liver of wild type mice ten minutes after injection, compared with $<1\%$ in *Oct1*$^{-/-}$ knockout mice[80]. Thus, the effects of metformin *in vivo* are likely to be restricted to the liver, whereas other compounds will also activate AMPK in other organs or cell types. In addition, since metformin activates AMPK indirectly by inhibiting the respiratory chain and thus increasing cellular AMP and ADP[41], it is likely that it has many "off-target" or AMPK-independent effects; indeed the acute effects of metformin on hepatic glucose production[81], as opposed to its longer-term effects on hepatic insulin sensitivity[82], appear to be independent of AMPK. Similarly, although salicylate does bind directly to AMPK, being a particularly small molecule it is unlikely to bind to any target

with high affinity, and it almost certainly has several AMPK-independent effects. Acetyl salicylate (aspirin) is, of course, already known to inhibit cyclo-oxygenases and hence prostanoid biosynthesis, although salicylate itself is a relatively poor cyclo-oxygenase inhibitor[83]. The different pharmacological effects of these AMPK activators may therefore be due to a combination of different pharmacokinetics, and distinct AMPK-independent effects.

5. Domain architecture and structure of AMPK

5.1. *The α subunits*

Each AMPK-α subunit contains at the N-terminus a typical eukaryotic kinase domain, with a conventional small N-lobe consisting mainly of β-sheets, followed by the larger C-lobe consisting mainly of α-helices. In the most recent crystal structures[38,65,74,84], such as that shown in Fig. 2, the kinase had been crystallized in the presence of the non-specific, ATP-competitive kinase inhibitor staurosporine, and as expected this was located in the ATP-binding cleft between the N- and C-lobes. The critical phosphorylation site, Thr172, is located in the "activation loop", a sequence region that must be phosphorylated in many kinases before they become active. Most of the crystal structures of AMPK were obtained with Thr172 phosphorylated and the activation loop was well ordered, although in at least one structure in the unphosphorylated state the activation loop was partially disordered[84]. The α subunit kinase domain (α-KD) is immediately followed by the auto-inhibitory domain (α-AID), so-called because bacterially expressed α-KD:α-AID constructs are about 10-fold less active than constructs containing the α-KD only, even when both have been phosphorylated on Thr172[62,85]. There is now good evidence that the α-AID inhibits the α-KD when AMP is not bound to the γ subunit, thus explaining the 10-fold allosteric activation by AMP. Crystal structures of α-KD:α-AID constructs from the AMPK ortholog from the fission yeast *Schizosaccharomyces pombe*[86], and more recently from humans[84], show that in this low activity state the α-AID, a bundle of three short α-helices, binds to the α-KD on the opposite surface to the catalytic cleft, with the α3 helix of the α-AID interacting with the N-lobe and the hinge between the N- and C-lobes (Fig. 3A). By comparing many structures of kinase domains in active and inactive conformations, it has been found that four hydrophobic residues termed the "regulatory spine" are universally aligned in active conformations, indicating that the active site is correctly disposed for activity, but that these residues are out of alignment in inactive conformations[87]. In the structures of the inactive α-KD:α-AID constructs of AMPK, the four residues that form the "regulatory spine" (Leu68 and Leu79 from the N-lobe, and His137 and Phe158 from the C-lobe) are not aligned (Fig. 3A). By contrast, in all structures of AMPK heterotrimers in active states, which are phosphorylated on Thr172 and have AMP bound to the γ subunit (see below), the α-AID has undergone a rotation such that helix α3 now interacts primarily with the γ subunit rather than with the N-lobe of the α-KD. At the same time the α-KD switches to



Figure 2 Structure of complete α1β2γ1 heterotrimer of AMPK. The model was created with MacPyMol using PDB file 4RER[84]. All molecules are shown in "sphere view", omitting hydrogen atoms. Domains of the heterotrimer are color coded and labeled as decribed in the text, whereas ancillary ligands (β-cyclodextrin, staurosporine and AMP) are shown with carbon atoms in light gray, oxygen in red and nitrogen in blue. AMP in site 3 is just visible beneath α-RIM2, while AMP in sites 1 and 4 are located around the other side of the γ1 subunit.



Figure 3 Two views of the kinase and auto-inhibitory domains of the α subunit (α-KD:α-AID) in inactive (A) and active (B) conformations. Note the major rotation of the α-AID relative to the α-KD between the two models; in (A), α-AID helix α3 interacts mainly with the α-KD small lobe (and with the hinge between the small and large lobes), but in (B) it interacts mainly with the γ subunit (not shown) instead. Note also that the four side chains of the "regulatory spine" (in white, red, magenta and blue) are out of alignment in (A) but are stacked in alignment in (B), indicating an active conformation[87]. The models were created with MacPyMol using PDB files 4RED (A) and 4RER (B)[84], and are shown in "cartoon" view except for the four residues that form the "regulatory spine" which are in "sphere" view. The view in (A) is of a structure derived from a construct containing only the α-KD and α-AID of human AMPK-α1. The structure crystallized as a dimer, and the α-KD shown is from one molecule while the α-AID shown is from the other molecule within the dimer. Nevertheless, the α-KD:α-AID construct behaved as a monomer in solution[84], and the structure is very similar to that of an α-KD:α-AID from *S. pombe*[86], where the arrangement of the α-AID and α-KD from the same molecule were very similar to that shown here. The view in (B) is of the same structure shown in Fig. 2, but only the α-KD and α-AID are shown.

an active conformation, where the four residues of the regulatory spine are now stacked in alignment (Fig. 3B).

The α-AID is connected to the α subunit C-terminal domain (α-CTD) by the α-linker, a region of extended polypeptide that wraps around one face of the γ subunit (Fig. 2) and is crucial in the mechanism for activation by AMP (discussed in more detail in Section 5.3). The α-CTD is a small globular domain that forms the interface with the C-terminal domain of the β subunit. An interesting feature of the α-CTD is that it ends in both the α1 and α2 isoforms with well-defined nuclear export sequences, although these have only been shown to be functional in the case of α2[88]. Both isoforms also contain serine/threonine-rich sequences of about 50 residues that we term the ST loops[89], which are discussed in Section 6 below.

5.2. *The β subunits*

When β subunit sequences are compared across isoforms and species, they contain two conserved regions, a central carbohydrate-binding module (β-CBM) and the C-terminal domain (β-CTD). The latter is a small compact domain that interacts with the α-CTD, and also contributes to an intrasubunit β-sheet containing two strands from the β-CTD and one from the N-terminus of γ. This architecture for assembling the three subunits is highly conserved throughout eukaryotes, from budding yeast[90] to fission yeast[91] and humans[92]. The β-CTD can be considered to form the core of the heterotrimeric AMPK complex, bridging the α and γ subunits.

The β-CBM is interesting because it is a member of the CBM48 family of carbohydrate-binding modules, non-catalytic domains usually found in enzymes that metabolize α1→6 linkages in carbohydrates, such as glycogen-branching enzymes and isoamylases[93]. The β-CBM causes a proportion of cellular AMPK to bind to glycogen particles[94,95], particularly in the case of the β2 isoform[94] whose CBM appears to have a higher affinity for glycogen than that in β1[96]. The carbohydrate-binding site is well defined, since crystal structures of isolated β-CBMs and a heterotrimeric α1β2γ1 complex (Fig. 2) have been solved in the presence of β-cyclodextrin, a circular heptasaccharide of α1→4-linked glucose units[84,97,98]. Until recently it had been unclear why only a proportion of AMPK in the cell is bound to glycogen, especially in skeletal muscle where β2 is the main β subunit isoform and where glycogen content can be very high. However, a recent paper shows that activated AMPK can autophosphorylate at Thr148 located within the β-CBM of β1[99], a residue known to be directly involved in the carbohydrate-binding site[97]. Phosphorylation at Thr148 prevents AMPK from binding to glycogen, although AMPK already bound to glycogen appears to be protected against autophosphorylation at this site[99].

CBMs are present within the subunits of all eukaryotic AMPK orthologs, although higher plant orthologs contain unusual "βγ" subunits that contain a CBM fused at the N-terminus of a γ subunit, as well as more conventional β subunits with central CBMs[100]. The universal occurrence of CBMs within AMPK orthologs suggest that they have key physiological functions, although these remain incompletely understood. Since both the skeletal muscle (GYS1)[101,102] and liver (GYS2)[103] isoforms of glycogen synthase are physiological targets that are inactivated after phosphorylation by AMPK, one function may be to co-localize AMPK with this glycogen-bound substrate. It has also

been suggested that the β-CBM may allow AMPK to sense the structural state of glycogen and regulate glycogen synthesis according to the status of glycogen stores[104,105], although further work is required to confirm that hypothesis.

Despite the uncertain role of glycogen binding, another function of the β-CBM has become clear with exciting findings that a cleft between it and the N-lobe of the α-KD form the binding site for A-769662, 991 and salicylate[65,74]. This cleft forms between the surface of the β-CBM opposite to the known carbohydrate-binding site, and the surface of the KD N-lobe opposite to the catalytic site. In the structure shown in Fig. 2, where the cleft was unoccupied, an electrostatic interaction between Lys29 and Lys31 from the N-lobe and the phosphate group on Ser108 of the β-CTD appeared to stabilize the interaction between the two domains[84]. In other structures, the side chain of Lys29 interacts with the carboxylate group at one end of 991, while the side chains of Lys29 and Lys31 are involved with the interaction with A-769662[65,74]. These findings help to explain the requirement for autophosphorylation of Ser108 for full activation by A-769662[75]. Based on a crystal soaked with iodosalicylate, salicylates also appear to bind in this site, although the resolution was not sufficient to analyze the detailed molecular interactions[74].

5.3. *The γ subunits*

The γ subunits contain at their C-terminal end four tandem repeats, termed cystathionine-beta-sythase 1 (CBS1) through CBS4, of a sequence motif of around 60 residues known as a CBS repeat. First recognized by bio-informatic analysis[106], CBS repeats also occur in a small number of other proteins in the human genome. Most CBS-containing proteins have only two repeats that assemble into a structure known as a Bateman domain, with the cleft between the repeats often binding regulatory ligands containing adenosine, such as ATP or S-adenosyl methionine[107]. The γ subunits of AMPK and its orthologs are unusual in that they contain four repeats, thus generating two Bateman domains formed by CBS1/CBS2 and CBS3/CBS4 respectively. These assemble in a head-to-head manner to form a disc-like shape, with one CBS repeat in each quadrant of the disk; these are color-coded in Fig. 2, although much of CBS1, CBS2 and CBS3 are hidden in the view shown. This arrangement generates four pseudosymmetrical clefts in the center where ligands might bind, two accessible from one side of the disc and two from the other. Isolated γ subunits were originally reported to competitively bind just two molecules of AMP or ATP[107], but when the core of the AMPK heterotrimer was crystallized in the presence of AMP, it was found to have three molecules of AMP bound in sites 1, 3 and 4 (the sites are numbered by convention according to the CBS repeat bearing an aspartate side chain that interacts with the ribose ring of the nucleotide; site 2 lacks an aspartate and appears to be unused). In the view shown in Fig. 2, part of a molecule of AMP is just visible in site 3, while sites 1 and 4 are hidden around the back of the γ subunit. Soaking of ATP into crystals made with AMP displaced AMP by ATP in sites 1 and 3, but not 4, leading to the idea that site 4 contains a permanently bound, "non-exchangeable" AMP[92] and perhaps explaining why only two sites were detected in the original binding studies[107]. However, when another group crystallized the core complex with ATP (as opposed to soaking ATP into crystals made with AMP), they found that ATP was bound at sites 1 and 4, while site 3 was empty[108].

The extended α-linker that connects the AID to the α-CTD (see Section 5.1) can be seen from the viewpoint of Fig. 2 to wrap around the front face of the γ subunit. One conserved region within this linker termed α-regulatory subunit interacting motif-1 (α-RIM1) interacts with the unused site 2, while another (α-RIM2) interacts with site 3. A highly conserved glutamate in α-RIM2 (Glu364 in human α1) interacts with Arg70 and Lys170 in γ1, which in turn interact with the phosphate group of AMP bound in site 3. This AMP- and site 3-dependent interaction between the γ subunit and the α-linker is proposed to cause the AID to move away from its inhibitory position behind the N-lobe of the kinase domain (Fig. 3A) into the position shown in Fig. 3B, thus explaining allosteric activation by AMP. If binding of ATP at site 3 did not allow the interaction with α-RIM2, this would also explain how ATP antagonizes activation by AMP. A variety of evidence now strongly supports this model:

(1) Mutations in both α-RIM1 and α-RIM2 expected to reduce interaction with the γ subunit (including mutation of Glu364), or their replacement by a shorter artificial linker, abolished allosteric activation by AMP[74,109].
(2) Singlet oxygen-mediated luminescence energy transfer (AlphaScreen) assays, which can monitor changes in the distance between donor and acceptor probes, were used to analyze interactions between a core α1β2γ1 heterotrimer (consisting of just the α- and β-CTDs and full length γ1) and a construct containing the AID, α-RIM1 and α-RIM2 from α1. Addition of AMP increased the interaction, whereas ATP decreased it.
(3) As mentioned in Section 4.2, the AMP analog C2 is rather selective for α1 complexes, with which it causes both allosteric activation and protection against dephosphorylation of Thr172. However, both effects of C2 could be transferred to α2 complexes merely by replacing α-RIM2 and the remainder of the α-linker from α2 with the equivalent region from α1. These results emphasize the importance of the α-linker in the dual mechanisms of activation by this AMP analog.

This model was also supported by AlphaScreen assays in which the donor and acceptor probes were attached to the N-termini of the α and γ subunits in a complete heterotrimer[84]. Addition of AMP yielded changes indicating that the probes moved together, suggesting the formation of a more compact conformation for the heterotrimer in the presence of AMP, as suggested by previous results obtained by small angle X-ray scattering in solution[110]. On the other hand, addition of ATP caused the probes to move apart, indicating a less compact conformation. This is consistent with the idea that the α-linker dissociates from the γ subunit in the inactive conformation in the presence of ATP, allowing the whole heterotrimer to adopt a more extended structure in which the AID interacts with and inhibits the kinase domain. These AlphaScreen assays also allowed the concentration dependence of the effects of AMP and ATP on these conformational changes to be measured, independently of their binding at the catalytic site. The results showed that the half-maximal effect (EC_{50}) for the effect of AMP (measured in the absence of ATP) occurred at 0.95 μmol/L, whereas the EC_{50} for the effect of ATP was at 0.85 mmol/L, almost 1000-fold higher[84]. For comparison (although it is not possible to measure allosteric activation in the absence of ATP) the estimated EC_{50} values for allosteric activation of γ1 complexes by AMP in the presence of 0.2, 1 and 5 mmol/L ATP were 5.3, 22 and 140 μmol/L, showing that increasing concentrations of ATP compete with AMP at the γ subunit sites[36].

5.4. *Remaining challenges in understanding regulation by adenine nucleotides*

Although the various crystal structures obtained over the last few years have yielded considerable insight into the mechanism of regulation by

adenine nucleotides, several questions remain. One is the role of binding of AMP and other nucleotides at sites 1 and 4, especially given the evidence discussed in Section 5.3 that binding at site 3 recruits the α-RIM1 motif, which is crucial both for allosteric activation and for protection against dephosphorylation. Interestingly, mutation to alanine of any one of the three aspartate residues that bind the ribose rings of nucleotides at sites 1, 3 and 4 abolishes both allosteric activation and promotion of Thr172 phosphorylation[111]. The three nucleotide binding sites are located close together at the center of the γ subunit, and side chains of highly conserved basic residues from the γ subunit interact with phosphate groups of nucleotides in more than one site. For example, the side chains of His151 and His298 in human γ1 interact with phosphate groups of AMP in both sites 1 and 4[92]. It therefore seems very likely that binding of nucleotides at these three sites will show mutual dependencies on each other, either positive or negative. Along these lines, the group who crystallized the core complex in the presence of ATP suggested that the mode of binding of ATP at site 4 would preclude binding of AMP (or any other nucleotide) at site 3. Thus, AMP may have to be bound at site 4 (and possibly also at site 1) before it binds at the crucial site 3.

Another question not full answered is how binding of AMP inhibits Thr172 dephosphorylation. Since the lack of ability of the AMP analog C2 to protect against dephosphorylation of α2 complexes can be restored by replacing α-RIM2 of α2 (which binds site 3 when AMP is bound) with the equivalent region from α1, it appears that it is binding of AMP at site 3 that is crucial for the effect. However, unlike allosteric activation by AMP, which does not require the presence of the β-CBM[94], protection against Thr172 dephosphorylation by AMP does require it[65], although the reasons for this are poorly understood.

Another puzzle is why ADP binding should provide protection against dephosphorylation of Thr172[38] yet does not, like AMP binding, cause allosteric activation. This would be hard to explain if the effects of ADP and AMP were due to binding at the same site. However, studies of the budding yeast ortholog of AMPK suggest that the γ subunit SNF4 is not required for the response to glucose starvation[112], and that binding of ADP to the catalytic site on the kinase domain, rather than to the γ subunit, may be responsible for its ability to protect against dephosphorylation of the site equivalent to Thr172[113]. In the same study, it was reported that binding of the kinase inhibitor staurosporine (which binds at the catalytic site[38]) to either the budding yeast or mammalian kinases provides protection against Thr172 dephosphorylation. Thus, it is possible that AMP and ADP protect against dephosphorylation by binding at different sites.

A final question that has not yet been illuminated by the structural studies concerns how phosphorylation of Thr172 by LKB1, but not CaMKKβ, is promoted by binding of AMP[36]. A radical proposal to explain this, which has been developed by Lin and colleagues[114,115] at Xiamen University, is that AMP binding to AMPK causes it to co-localize with LKB1 due to their mutual interactions with the scaffold protein axin, which in turn binds to late endosomal/lysosomal adaptor and MAPK and mTOR activator (LAMTOR1) at the surface of the lysosome. However, promotion by AMP of Thr172 phosphorylation by LKB1 can be observed on reconstitution of highly purified LKB1 and AMPK[36], suggesting that the effect does not strictly require any of these additional components.

6. Non-canonical regulation by phosphorylation of the ST loop and other sites

The hormone insulin represents a signal that nutrients are available, with those nutrients (glucose, amino acids and fats) either directly triggering insulin release from the β cells of the pancreas, or doing so indirectly *via* release of incretins such as glucagon-like peptide-1 from the small intestine. Insulin then stimulates target cells to take up these nutrients and convert them to their storage forms of glycogen, triglycerides and proteins. Insulin-like growth factor-1 (IGF1), which acts *via* a signaling pathway closely related to that of insulin, is a growth factor that promotes biosynthesis and hence cell growth. Since AMPK is generally switched on under the opposite circumstances to insulin and IGF1 (lack of nutrients or energy) it is not surprising that the AKT/PKB (protein kinase B) pathway, the principal signaling pathway downstream of insulin and IGF1, should antagonize the AMPK pathway. In 2006 it was reported that AKT phosphorylated rat AMPK-α1 at Ser485 (equivalent to Ser487 in humans, with human numbering being used below, with the exception of Thr172). Evidence was presented that prior phosphorylation at Ser487 by AKT reduced subsequent phosphorylation at Thr172 and consequent activation by LKB1, and that this mechanism explained how prior treatment of perfused rat heart with insulin reduced AMPK activation during subsequent ischemia[116].

Ser487 occurs within a region of around 50 – 55 residues in the AMPK-α subunits that we now term the "ST loop". This is a serine/threonine rich region that is present in α-CTDs in all vertebrates and nematodes, but not in orthologs from insects, plants, fungi or protozoa. In all crystal structures of mammalian complexes containing an α-CTD, the ST loop was either not resolved, suggesting that it is disordered within the crystals (perhaps because it is not phosphorylated during bacterial expression), or had been replaced by a short artificial spacer in the construct crystallized, because it was thought that it might hinder crystallization. In these structures the ST loop therefore appears as a gap between the end of penultimate β-strand and the start of the last α-helix in the α-CTD. My group[89] has recently confirmed that AKT efficiently phosphorylates Ser487 on AMPK-α1, although the equivalent residue on AMPK-α2, Ser491, is an extremely poor substrate for AKT—it is therefore important not to simply assume that the regulation of α1 and α2 by phosphorylation in this region will be identical. In fact, Ser491 on α2 is efficiently autophosphorylated by AMPK itself, and becomes phosphorylated in intact cells when AMPK, rather than AKT, is activated. By generating HEK-293 cells expressing wild type or mutant α1, we showed that prior activation of AKT using IGF1 inhibited subsequent Thr172 phosphorylation and AMPK-α1 activation in response to A-769662, and that this was blocked by a specific AKT inhibitor or by mutation of Ser487 to alanine. We also showed that the effect of Ser487 phosphorylation by AKT to inhibit subsequent phosphorylation at Thr172 on AMPK-α1 was identical using either LKB1 or CaMKKβ as the upstream kinase, suggesting that the mechanism may involve a simple physical occlusion of Thr172. Consistent with this, mutation of three basic residues in the α-C helix of the N-lobe, which are conserved in all vertebrate AMPK-α subunits but not in closely related kinases, abolished the inhibitory effect of AKT even though Ser487 was still phosphorylated. This suggested that the ST loop interacts with the α-C helix following its phosphorylation, thus reducing access to Thr172[89].

ST loops also appear to be phosphorylated by other kinases. Hurley et al.[117] reported that Ser487/491 on AMPK-α1 or -α2 (isoform not specified) was phosphorylated in response to cyclic AMP elevation in INS1 cells, a pancreatic β cell line, while a recombinant AMPK-α1 peptide was phosphorylated in cell-free assays at Ser487 by cyclic AMP-dependent protein kinase (PKA).

Complicating this story, however, the effects of cyclic AMP-elevation were abolished in *CaMKKβ*-null mouse embryo fibroblasts, and CaMKKβ was inactivated by cyclic AMP-elevating agents, suggesting that effects in intact cells were mediated by modulation of CaMKKβ, rather than AMPK[117]. Using a bacterially expressed α1β1γ1 complex, PKA has been reported to phosphorylate not only Ser487 but also Ser499 and Ser175, and it was proposed that this limited AMPK activation, and hence inhibition of lipolysis, when PKA was activated in white adipocytes[118]. Like Ser487, Ser499 is located in the ST loop, but Ser175 is immediately adjacent to Thr174, the residue equivalent to Thr172 in human α1. Based on analysis of various mutations, the authors[118] suggested that it was phosphorylation at Ser175 rather than Ser487 or Ser499 that blocked subsequent AMPK activation. A puzzling feature is why they did not observe any effects on subsequent Thr172 phosphorylation when Ser487 was phosphorylated by PKA, even though two other groups[89,116] have shown that there is a marked effect when Ser487 is phosphorylated by AKT. Finally, it has been reported that two residues in the ST loop just upstream of Ser487, *i.e.,* Thr481 and Ser477, are phosphorylated by glycogen synthase kinase 3 (GSK3) when Ser487 has been phosphorylated[119]. GSK3 often phosphorylates serine or threonine side chains 4 residues N-terminal to a "priming" phosphoamino acid, although the spacing between Ser487 and Thr481 is six rather than four residues. It was proposed that phosphorylation of Ser477 and Thr481 inhibited net Thr172 phosphorylation by promoting its dephosphorylation. While these observations are interesting, the physiological rationale underlying inhibition of AMPK by GSK3 is difficult to grasp, because both GSK3 isoforms (α and β) are inactivated by phosphorylation by AKT, and because GSK3 usually acts to inhibit rather than promote anabolic pathways, similar to AMPK but opposite to AKT.

7. Regulation of AMPK by natural products used in traditional medicines

As mentioned in Section 4.1, over the last few years more than 100 different natural products have been shown to activate AMPK; a list of these, which is almost certainly not comprehensive, is shown in Table 1[41,44,49,50,59,60,69,120–249]. Although many of them can be classed as polyphenols, their structures are very varied. The majority are products of plants used in herbal remedies, particularly in traditional Asian medicine. The mechanism by which most of them activate AMPK is unknown, and a puzzling feature is why so many natural plant products should all be AMPK activators. One clue is that among the small number of these activators where the mechanism has been established (given at the top of the list in Table 1), most are inhibitors of mitochondrial ATP synthesis, either by inhibiting Complex I of the respiratory chain, or by inhibiting the ATP synthase (Complex V). Most of the natural plant products that activate AMPK appear to be secondary metabolites, *i.e*., they are not required for plant growth, development or reproduction, and a reasonable working hypothesis is that many of them are molecules produced by plants to deter infection by pathogens, or grazing by insect or other herbivorous animals, to whom these molecules are toxic. In support of this idea, resveratrol is known to be produced by grapes in response to fungal infection[250], while *Galega officinalis,* the source of galegine from which metformin and phenformin were derived, is classified as a noxious weed in the USA because it is poisonous to herbivorous animals (reflected in one of the common names for *Galega officinalis*, Goat's Rue).

Why should plants produce inhibitors of mitochondrial function as defensive chemicals? The respiratory chain and the ATP synthase contain five large hydrophobic multiprotein complexes, with Complex I containing no less than 44 protein subunits, while the ATP synthase has at least 14. It seems probable that many different hydrophobic, xenobiotic compounds might find a binding site in one or more of these complexes that would inhibit their function. Many secondary metabolites of plants are stored in the cell vacuole (equivalent to the lysosome of animal cells), and are therefore kept away from their own mitochondria. The production of mitochondrial poisons might therefore be a useful general approach for plants to produce compounds that would deter infection or grazing. However, in line with the aphorism of Paracelsus that "the dose makes the poison", lower doses of these compounds that are not sufficient to fully inhibit mitochondrial function might still have useful therapeutic effects by activating AMPK.

It is also interesting to note that the barbiturate drug, phenobarbital, activates AMPK in an AMP-dependent manner by inhibiting the respiratory chain[41]. In hepatocytes, AMPK activation is required for phenobarbital to induce expression of genes (*e.g.*, *CYP2B6*) encoding enzymes of the cytochrome P450 (CYP) family, *via* the constitutively active/androstane receptor, constitutive active/androstane receptor (CAR)[251,252]. Some classes of CYP enzymes (especially the CYP1/CYP2/CYP3 families) catalyze the initial steps in metabolism of drugs and other hydrophobic xenobiotics, making them more soluble for excretion. Plant products that are defensive agents inhibiting mitochondrial ATP synthesis would activate AMPK, and induction of CYP enzymes by AMPK might then be a good general way for the animal to mount a response to deal with potential poisoning by these xenobiotics.

8. Conclusions and perspectives

Most indications for drugs targeting AMPK suggest that activators rather than inhibitors would be therapeutically beneficial. In general, development of activators is probably more difficult than development of inhibitors, but the fact that there are already many known activators of AMPK, acting by three or four different mechanisms, shows that this goal is reachable. Many of the activators already known are natural plant products, or derivatives of natural products, that originate from traditional medicines. Two of these, metformin and salicylate, are already among the most successful and widely used drugs of all time, although the extent to which their therapeutic effects are mediated by AMPK is still being debated. Of the many natural plant products whose mechanism of activation of AMPK has not yet been elucidated, my suspicion is that most of them will turn out to be compounds used by plants for defensive purposes, most of which are likely to activate AMPK indirectly by inhibiting mitochondrial ATP synthesis. In such cases, the question must always be asked whether the new agent is more effective than metformin, and whether it has fewer side effects. However, there may also be some direct activators among the long list of natural products in Table 1, and this is certainly an avenue worth pursuing. Of the known binding sites on AMPK where ligand binding can cause activation, the A-769662/salicylate-binding site is perhaps the easiest to target for drug development, although the AMP-binding sites can also be targeted by pro-drugs such as AICAR or C13. It will be fascinating to see whether the current effort to develop novel AMPK activators will result in any clinically useful drugs over the next few years.

Table 1 Partial list of natural products (mostly from plants) that have been reported to activate AMPK in intact cells or *in vivo*. Although a single source species is usually listed, most of the compounds are probably also produced by related species. The author compiled this list but has not read all of the papers cited as thoroughly as other papers discussed in this review. ?, unkown.

Natural product	Source	Mechanism	Ref.
Antimycin A	*Streptomyces* (bacteria)	Inhibits Complex III	44
Apoptolidins A/C	*Nocardiopsis spp.* (bacteria)	Inhibits ATP synthase	120
Arctigenin	*Arctium lappa*	Inhibits Complex I	49,121
Berberine	*Berberis spp.*, other plants	Inhibits Complex I	41,122
Cordycepin (3′-deoxyadenosine)	*Cordyceps militaris* (fungus)	Converted to AMP analog?	59,60,123
Galegine	*Galega officinalis*	Inhibits Complex I	50
Oligomycin	*Streptomyces* (bacteria)	Inhibits F1 ATP synthase	41
Quercetin	Many plants	Inhibits Complex I	124
Resveratrol	Grapes, red wine	Inhibits ATP synthase	41,125,126
Salicylate	*Salix alba* (willow), other plants	Binds to A-769662 site	69
Alternol	*Alternaria alternata*	?	127
Anthocyanin fraction	Purple sweet potato	?	128
Anthocyanin fraction	Korean black bean	?	129
Apigenin	*Matricaria chamomilla*	?	130
Artemisinin	*Artemisia annua*	?	131
Aspalathin	*Aspalathus linearis*	?	132
Bavachalcone	*Psoralea corylifolia*	?	133
Caffeic acid	All plants	?	134
Caffeic acid, phenethyl and phenylpropyl esters	All plants	?	135
Celastrol	Many plants	?	136
Chalcones	Various plants	?	137
Chitosan	Crustaceans	?	138
Chrysin	*Passiflora caerulea*	?	139
Cucurbitane triterpenoids	*Siraitia grosvenorii*	?	140
Curcumin	*Curcuma longa*	?	141,142
Cyanidin	*Daucus carota* (black carrot)	?	143
Dehydrozingerone	*Zingiber officinale* (ginger)	?	144
Delphinidin-3-glucoside	Many plants	?	145
14-Deoxyandrographolide	*Andrographis paniculata*	?	146
Dihydromyricetin	*Ampelopsis grossedentata*	?	147
2-(2,4-Dihydroxyphenyl)-5-(*E*)-propenylbenzofuran	*Krameria lappacea*	?	148
Emodin	*Rheum emodi*	?	149–151
ENERGI-F704	Bamboo	?	152,153
Epigallocatechin gallate	*Camellia sinensis*	?	124,154
Ergostatrien-3β-ol	*Antrodia camphorata*	?	155
Eugenol	Clove oil, nutmeg, cinnamon, basil	?	156
Fargesin	*Magnolia spp.*	?	157
Foenumoside B	*Lysimachia foenum-graecum*	?	158
Fucoidan	Brown seaweeds	?	159
Fungal extract	*Clitocybe nuda*	?	160,161
Gallic acid	Many plants	?	162
Geraniol	Rose/palmarosa/citronella oils	?	163
GGEx18	Traditional Korean medicine	?	164
6-Gingerol	*Zingiber officinale* (ginger)	?	165–167
Ginsenosides	*Panax ginseng*	?	168 – 172
Glabridin	*Glycyrrhiza glabra*	?	173,174
Green tea extract	*Camellia sinensis*	?	175,176
Hispidulin	*Saussurea involucrate*	?	177–179
Honokiol	*Magnolia grandiflora*	?	180,181
Hugan Qingzhi tablet	Chinese herbal medicine	?	182
Indazole-type alkaloids	*Nigella sativa*	?	183
Isoquercitrin	Many plants	?	184
Isorhamnetin	*Tagetes lucida*	?	185
Jinlida granule	Chinese herbal medicine	?	186
Jinqi formula	*Coptidis rhizome*/*Astragali rhadix*/*Lonicerae japonicae*	?	187
Karanjin	*Pongamia pinnata*	?	188
Kazinol C	*Broussonetia kazinoki*	?	189

Table 1 (*continued*)

Natural product	Source	Mechanism	Ref.
Licochalcone	*Glycyrrhiza glabra* (licorice)	?	190
Lindenenyl acetate	*Lindera strychnifolia*	?	191
Luteolin	Many plants	?	124
Malvidin	*Daucus carota* (black carrot)	?	143
Mangiferin	*Iris unguicularis*	?	192–195
Methyl cinnamate	*Zanthoxylum armatum*	?	196
4-*O*-methylhonokiol analog	*Magnolia grandiflora*	?	197
2-Methyl-7-hydroxymethyl-1,4-naphthoquinone	*Pyrola rotundifolia*	?	198
Monascin/ankaflavin	*Monascus pilosus* (a fungus)	?	199
Monascuspiloin	*Monascus pilosus* (a fungus)	?	200
Naringin	*Citrus x paradisi*	?	201
Nectrandin B	*Myristica fragrans* (nutmeg)	?	202–204
Octaphlorethol A	*Ishige foliacea* (a brown alga)	?	205
Oleanolic acid	Many plants	?	206
Osthole	*Cnidium monnieri*	?	207,208
Parthenolide	*Tanacetum parthenium* (feverfew)	?	209
Persimmon tannin	*Diospyros kaki* (persimmon)	?	210
Petasin	*Petasites spp.*	?	211
Piperlongumine	*Piper longum*	?	212
Plant extract	*Boesenbergia pandurata*	?	213
Plant extract	*Cirsium japonicum*	?	193
Plant extract	*Houttuynia cordata*	?	214
Plant extract	*Impatiens balsamina*	?	215
Plant extract	*Lycium barbarum*	?	216
Plant extract	*Malva verticillata*	?	217
Plant extract	*Remotiflori radix*	?	218
Plant extract	*Rhus verniciflua Stokes*	?	219
Plant extract	*Scutellaria baicalensis*	?	220
Plant extract	*Sechium edule*	?	221
Plant extract	*Taraxacum mongolicum*	?	222
Plant extract	*Theobroma cacao* (cocoa)	?	223
Plant extract	*Viola mandshurica*	?	224
Plant extract	*Vitis thunbergii*	?	225
Pomolic acid	*Chrysobalanus icaco*	?	226
Pterostilbene	Grapes, other fruits	?	227
Puerarin	*Radix puerariae*	?	228
ReishiMax	*Ganoderma lucidum*	?	229
Rhizochalin (aglycone)	*Rhizochalina incrustata* (a sponge)	?	230
S-methylmethionine sulfonium chloride	Many plants	?	231
Salidroside	*Rhodiola rosea*	?	232
Saponins	*Rubus parvifolius*	?	233
Scopoletin	*Scopolia spp.*	?	234
Soybean peptides	*Glycine max (soybean)*	?	235
Sulforaphane	*Brassica oleracea*	?	236
Tangeretin	*Citrus tangerine* (tangerine)	?	237
Tanshinone IIA	*Salvia miltiorrhiza*	?	238,239
Theaflavins	*Camellia sinensis* (tea)	?	240
Theasinsensins	*Camellia sinensis* (tea)	?	241
Thymoquinone	*Nigella sativa*	?	242
Tiliroside	Rose hips, strawberry, raspberry	?	243
Tormentic acid	*Eriobotrya japonica*	?	244
Trans-cinnamic acid	Cinnamon	?	245
Triterpenoid saponins	*Stauntonia chinensis*	?	246
Ursolic acid	*Mirabilis jalapa*, other plants	?	247,248
Xanthigen	*Punica granatum*	?	249

Acknowledgments

Grahame Hardie is funded by a Senior Investigator Award (No. 097726) from the Wellcome Trust and a programme grant (No. C37030/A15101) from Cancer Research UK. I would like to thank all of the current members of my laboratory (Romana Auciello, Alex Gray, Fiona Ross, Fiona Russell, Graeme Gowans, Simon Hawley and Diana Vara-Ciruelos) for discussions that have helped in putting this review together.

References

1. Hardie DG. AMPK-sensing energy while talking to other signaling pathways. *Cell Metab* 2014;**20**:939–52.
2. Hardie DG. AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels. *Annu Rev Nutr* 2014;**34**:31–55.
3. Hardie DG. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. *Curr Opin Cell Biol* 2014;**33**:1–7.
4. Hardie DG. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. *J Intern Med* 2014;**276**:543–59.
5. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. *Nature* 2013;**493**:346–55.
6. Sim ATR, Hardie DG. The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase. *FEBS Lett* 1988;**233**:294–8.
7. Munday MR, Campbell DG, Carling D, Hardie DG. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. *Eur J Biochem* 1988;**175**:331–8.
8. Carling D, Zammit VA, Hardie DG. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. *FEBS Lett* 1987;**223**:217–22.
9. Birk JB, Wojtaszewski JFP. Predominant $\alpha 1/\beta 2/\gamma 3$ AMPK activation during exercise in human skeletal muscle. *J Physiol* 2006;**577**:1021–32.
10. Katinka MD, Duprat S, Cornillot E, Méténier G, Thomarat F, Prensier G, et al. Genome sequence and gene compaction of the eukaryote parasite *Encephalitozoon cuniculi*. *Nature* 2001;**414**:450–3.
11. Miranda-Saavedra D, Stark MJR, Packer JC, Vivares CP, Doerig C, Barton GJ. The complement of protein kinases of the microsporidium *Encephalitozoon cuniculi* in relation to those of *Saccharomyces cerevisiae* and *Schizosaccharomyces pombe*. *BMC Genomics* 2007;**8**:309.
12. Williams BAP, Cali A, Takvorian PM, Keeling PJ. Distinct localization patterns of two putative mitochondrial proteins in the microsporidian *Encephalitozoon cuniculi*. *J Eukaryot Microbiol* 2008;**55**:131–3.
13. Tsaousis AD, Kunji ERS, Goldberg AV, Lucocq JM, Hirt RP, Embley TM. A novel route for ATP acquisition by the remnant mitochondria of *Encephalitozoon cuniculi*. *Nature* 2008;**453**:553–6.
14. Haurie V, Boucherie H, Sagliocco F. The SNF1 protein kinase controls the induction of genes of the iron uptake pathway at the diauxic shift in *Saccharomyces cerevisiae*. *J Biol Chem* 2003;**278**:45391–6.
15. Zong HH, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. *Proc Natl Acad Sci U S A* 2002;**99**:15983–7.
16. Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle *via* direct phosphorylation of PGC-1α. *Proc Natl Acad Sci U S A* 2007;**104**:12017–22.
17. Cantó C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M, et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. *Cell Metab* 2010;**11**:213–9.
18. Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. *Bioessays* 2001;**23**:1112–9.
19. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat Rev Mol Cell Biol* 2012;**13**:251–62.
20. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, et al. Characterization of the AMP-activated protein kinase kinase from rat liver, and identification of threonine 172 as the major site at which it phosphorylates and activates AMP-activated protein kinase. *J Biol Chem* 1996;**271**:27879–87.
21. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, et al. et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. *J Biol* 2003;**2**:28.
22. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Curr Biol* 2003;**13**:2004–8.
23. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci U S A* 2004;**101**:3329–35.
24. Sakamoto K, Göransson O, Hardie DG, Alessi DR. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. *Am J Physiol Endocrinol Metab* 2004;**287**:E310–7.
25. Sakamoto K, McCarthy A, Smith D, Green KA, Hardie DG, Ashworth A, et al. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. *EMBO J* 2005;**24**:1810–20.
26. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, et al. Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. *Cell Metab* 2005;**2**:9–19.
27. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, et al. Ca^{2+}/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. *Cell Metab* 2005;**2**:21–33.
28. Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA. The Ca^{2+}/calmoldulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. *J Biol Chem* 2005;**280**:29060–6.
29. Kishi K, Yuasa T, Minami A, Yamada M, Hagi A, Hayashi H, et al. AMP-activated protein kinase is activated by the stimulations of G_q-coupled receptors. *Biochem Biophys Res Commun* 2000;**276**:16–22.
30. Stahmann N, Woods A, Carling D, Heller R. Thrombin activates AMP-activated protein kinase in endothelial cells *via* a pathway involving Ca^{2+}/calmodulin-dependent protein kinase kinase β. *Mol Cell Biol* 2006;**26**:5933–45.
31. Yang YL, Atasoy D, Su HH, Sternson SM. Hunger states switch a flip-flop memory circuit *via* a synaptic AMPK-dependent positive feedback loop. *Cell* 2011;**146**:992–1003.
32. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates SNF1 protein kinase in yeast and phosphorylates AMP-activated protein kinase *in vitro*. *J Biol Chem* 2006;**281**:25336–43.
33. Herrero-Martín G, Høyer-Hansen M, García-García C, Fumarola C, Farkas T, López-Rivas A, et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. *EMBO J* 2009;**28**:677–85.
34. Yeh LA, Lee KH, Kim KH. Regulation of rat liver acetyl-CoA carboxylase. Regulation of phosphorylation and inactivation of acetyl-CoA carboxylase by the adenylate energy charge. *J Biol Chem* 1980;**255**:2308–14.
35. Moore F, Weekes J, Hardie DG. Evidence that AMP triggers phosphorylation as well as direct allosteric activation of rat liver AMP-activated protein kinase. A sensitive mechanism to protect the cell against ATP depletion. *Eur J Biochem* 1991;**199**:691–7.
36. Gowans GJ, Hawley SA, Ross FA, Hardie DG. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. *Cell Metab* 2013;**18**:556–66.
37. Oakhill JS, Steel R, Chen ZP, Scott JW, Ling NM, Tam S, et al. AMPK is a direct adenylate charge-regulated protein kinase. *Science* 2011;**332**:1433–5.
38. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, et al. Structure of mammalian AMPK and its regulation by ADP. *Nature* 2011;**472**:230–3.

39. Oakhill JS, Scott JW, Kemp BE. AMPK functions as an adenylate charge-regulated protein kinase. *Trends Endocrinol Metab* 2012;**23**:125–32.
40. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. *Am J Physiol* 1999;**277**:E1–10.
41. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, et al. Use of cells expressing γ subunit variants to identify diverse mechanisms of AMPK activation. *Cell Metab* 2010;**11**:554–65.
42. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. *Biochem J* 2000;**348**:607–14.
43. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration *via* an indirect effect targeted on the respiratory chain complex I. *J Biol Chem* 2000;**275**:223–8.
44. Witters LA, Nordlund AC, Marshall L. Regulation of intracellular acetyl-CoA carboxylase by ATP depletors mimics the action of the 5′-AMP-activated protein kinase. *Biochem Biophys Res Commun* 1991;**181**:1486–92.
45. Gledhill JR, Montgomery MG, Leslie AGW, Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. *Proc Natl Acad Sci U S A* 2007;**104**:13632–7.
46. Jensen TE, Ross FA, Kleinert M, Sylow L, Knudsen JR, Gowans GJ, et al. PT-1 selectively activates AMPK-γ1 complexes in mouse skeletal muscle, but activates all three γ subunit complexes in cultured human cells by inhibiting the respiratory chain. *Biochem J* 2015;**467**:461–72.
47. Pang T, Zhang ZS, Gu M, Qiu BY, Yu LF, Cao PR, et al. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. *J Biol Chem* 2008;**283**:16051–60.
48. Turner N, Li JY, Gosby A, To SWC, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. *Diabetes* 2008;**57**:1414–8.
49. Huang SL, Yu RT, Gong J, Feng Y, Dai YL, Hu F, et al. Arctigenin, a natural compound, activates AMP-activated protein kinase *via* inhibition of mitochondria complex I and ameliorates metabolic disorders in *ob*/*ob* mice. *Diabetologia* 2012;**55**:1469–81.
50. Mooney MH, Fogarty S, Stevenson C, Gallagher AM, Palit P, Hawley SA, et al. Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice. *Br J Pharmacol* 2008;**153**:1669–77.
51. Jenkins Y, Sun TQ, Markovtsov V, Foretz M, Li W, Nguyen H, et al. AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes. *PLoS One* 2013;**8**:e81870.
52. Gadalla AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, et al. AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. *J Neurochem* 2004;**88**:1272–82.
53. Day P, Sharff A, Parra L, Cleasby A, Williams M, Hörer S, et al. Structure of a CBS-domain pair from the regulatory γ1 subunit of human AMPK in complex with AMP and ZMP. *Acta Crystallogr D Biol Crystallogr* 2007;**63**:587–96.
54. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? *Eur J Biochem* 1995;**229**:558–65.
55. Pirkmajer S, Kulkarni SS, Tom RZ, Ross FA, Hawley SA, Hardie DG, et al. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle *via* AMPK activation. *Diabetes* 2015;**64**:360–9.
56. Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. *Cancer Res* 2009;**69**:5467–74.
57. Gómez-Galeno JE, Dang Q, Nguyen TH, Boyer SH, Grote MP, Sun Z, et al. A potent and selective AMPK activator that inhibits *de novo* lipogenesis. *ACS Med Chem Lett* 2010;**1**:478–82.
58. Hunter RW, Foretz M, Bultot L, Fullerton MD, Deak M, Ross FA, et al. Mechanism of action of compound-13: an α1-selective small molecule activator of AMPK. *Chem Biol* 2014;**21**:866–79.
59. Guo P, Kai Q, Gao J, Lian ZQ, Wu CM, Wu CA, et al. Cordycepin prevents hyperlipidemia in hamsters fed a high-fat diet *via* activation of AMP-activated protein kinase. *J Pharmacol Sci* 2010;**113**:395–403.
60. Wu CM, Guo YS, Su Y, Zhang X, Luan H, Zhang XP, et al. Cordycepin activates AMP-activated protein kinase (AMPK) *via* interaction with the γ1 subunit. *J Cell Mol Med* 2014;**18**:293–304.
61. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. *Cell Metab* 2006;**3**:403–16.
62. Göransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. *J Biol Chem* 2007;**282**:32549–60.
63. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. *J Biol Chem* 2007;**282**:32539–48.
64. Scott JW, van Denderen BJW, Jorgensen SB, Honeyman JE, Steinberg GR, Oakhill JS, et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase β1-containing complexes. *Chem Biol* 2008;**15**:1220–30.
65. Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF, Underwood E, et al. Structural basis of AMPK regulation by small molecule activators. *Nat Commun* 2013;**4**:3017.
66. Lai YC, Kviklyte S, Vertommen D, Lantier L, Foretz M, Viollet B, et al. A small-molecule benzimidazole derivative that potently activates AMPK to increase glucose transport in skeletal muscle: comparison with effects of contraction and other AMPK activators. *Biochem J* 2014;**460**:363–75.
67. Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. *EMBO Mol Med* 2014;**6**:519–38.
68. Benziane B, Björnholm M, Lantier L, Viollet B, Zierath JR, Chibalin AV. AMP-activated protein kinase activator A-769662 is an inhibitor of the Na^+-K^+-ATPase. *Am J Physiol Cell Physiol* 2009;**297**:C1554–66.
69. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. *Science* 2012;**336**:918–22.
70. Jeffreys D. *Aspirin: the remarkable story of a wonder drug*. London: Bloomsbury Publishing; 2004.
71. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat New Biol* 1971;**231**:232–5.
72. Vane JR, Botting RM. The mechanism of action of aspirin. *Thromb Res* 2003;**110**:255–8.
73. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. *Eur J Pharmacol* 2002;**447**:1–9.
74. Calabrese MF, Rajamohan F, Harris MS, Caspers NL, Magyar R, Withka JM, et al. Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite poles by different molecular mechanisms. *Structure* 2014;**22**:1161–72.
75. Scott JW, Ling NM, Issa SMA, Dite TA, O'Brien MT, Chen ZP, et al. Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling. *Chem Biol* 2014;**21**:619–27.
76. Choi SL, Kim SJ, Lee KT, Kim J, Mu J, Birnbaum MJ, et al. The regulation of AMP-activated protein kinase by H_2O_2. *Biochem Biophys Res Commun* 2001;**287**:92–7.
77. Zmijewski JW, Banerjee S, Bae H, Friggeri A, Lazarowski ER, Abraham E. Exposure to hydrogen peroxide induces oxidation and

activation of AMP-activated protein kinase. *J Biol Chem* 2010;**285**:33154–64.
78. Auciello FR, Ross FA, Ikematsu N, Hardie DG. Oxidative stress activates AMPK in cultured cells primarily by increasing cellular AMP and/or ADP. *FEBS Lett* 2014;**588**:3361–6.
79. Shao D, Oka S, Liu T, Zhai PY, Ago T, Sciarretta S, et al. A redox-dependent mechanism for regulation of AMPK activation by thioredoxin1 during energy starvation. *Cell Metab* 2014;**19**:232–45.
80. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. *J Pharmacol Exp Ther* 2002;**302**:510–5.
81. Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway *via* a decrease in hepatic energy state. *J Clin Invest* 2010;**120**:2355–69.
82. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, et al. Single phosphorylation sites in ACC1 and ACC2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. *Nat Med* 2013;**19**:1649–54.
83. Higgs GA, Salmon JA, Henderson B, Vane JR, et al. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. *Proc Natl Acad Sci U S A* 1987;**84**:1417–20.
84. Li XD, Wang LL, Zhou XE, Ke JY, de Waal PW, Gu X. Structural basis of AMPK regulation by adenine nucleotides and glycogen. *Cell Res* 2015;**25**:50–66.
85. Pang T, Xiong B, Li JY, Qiu BY, Jin GZ, Shen JK, et al. Conserved α-helix acts as autoinhibitory sequence in AMP-activated protein kinase α subunits. *J Biol Chem* 2007;**282**:495–506.
86. Chen L, Jiao ZH, Zheng LS, Zhang YY, Xie ST, Wang ZX, et al. Structural insight into the autoinhibition mechanism of AMP-activated protein kinase. *Nature* 2009;**459**:1146–9.
87. Taylor SS, Kornev AP. Protein kinases: evolution of dynamic regulatory proteins. *Trends Biochem Sci* 2011;**36**:65–77.
88. Kazgan N, Williams T, Forsberg LJ, Brenman JE. Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase. *Mol Biol Cell* 2010;**21**:3433–42.
89. Hawley SA, Ross FA, Gowans GJ, Tibarewal P, Leslie NR, Hardie DG. Phosphorylation by AKT within the ST loop of AMPK-α1 down-regulates its activation in tumour cells. *Biochem J* 2014;**459**:275–87.
90. Amodeo GA, Rudolph MJ, Tong L. Crystal structure of the heterotrimer core of *Saccharomyces cerevisiae* AMPK homologue SNF1. *Nature* 2007;**449**:492–5.
91. Townley R, Shapiro L. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. *Science* 2007;**315**:1726–9.
92. Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C, et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. *Nature* 2007;**449**:496–500.
93. Koay A, Rimmer KA, Mertens HDT, Gooley PR, Stapleton D. Oligosaccharide recognition and binding to the carbohydrate binding module of AMP-activated protein kinase. *FEBS Lett* 2007;**581**:5055–9.
94. Hudson ER, Pan DA, James J, Lucocq JM, Hawley SA, Green KA, et al. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. *Curr Biol* 2003;**13**:861–6.
95. Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, et al. AMPK β subunit targets metabolic stress-sensing to glycogen. *Curr Biol* 2003;**13**:867–71.
96. Koay A, Woodcroft B, Petrie EJ, Yue H, Emanuelle S, Bieri M, et al. AMPK β subunits display isoform specific affinities for carbohydrates. *FEBS Lett* 2010;**584**:3499–503.
97. Polekhina G, Gupta A, van Denderen BJW, Feil SC, Kemp BE, Stapleton D, et al. Structural basis for glycogen recognition by AMP-activated protein kinase. *Structure* 2005;**13**:1453–62.
98. Mobbs JI, Koay A, di Paolo A, Bieri M, Petrie EJ, Gorman MA, et al. Determinants of oligosaccharide specificity of the carbohydrate binding modules of AMP-activated protein kinase. *Biochem J* 2015;**468**:245–57.
99. Oligschlaeger Y, Miglianico M, Chanda D, Scholz R, Thali RF, Tuerk R, et al. The recruitment of AMP-activated protein kinase to glycogen is regulated by autophosphorylation. *J Biol Chem* 2015;**290**:11715–28.
100. Emanuelle S, Hossain MI, Moller IE, Pedersen HL, van de Meene AM, Doblin MS, et al. SnRK1 from *Arabidopsis thaliana* is an atypical AMPK. *Plant J* 2015;**82**:183–92.
101. Carling D, Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. *Biochim Biophys Acta* 1989;**1012**:81–6.
102. Jørgensen SB, Nielsen JN, Birk JB, Olsen GS, Viollet B, Andreelli F, et al. The α2-5′AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. *Diabetes* 2004;**53**:3074–81.
103. Bultot L, Guigas B, von Wilamowitz-Moellendorff A, Maisin L, Vertommen D, Hussain N, et al. AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase. *Biochem J* 2012;**443**:193–203.
104. McBride A, Hardie DG. AMP-activated protein kinase-a sensor of glycogen as well as AMP and ATP? *Acta Physiol* 2009;**196**:99–113.
105. McBride A, Ghilagaber S, Nikolaev A, Hardie DG. The glycogen-binding domain on AMPK β subunit allows the kinase to act as a glycogen sensor. *Cell Metab* 2009;**9**:23–34.
106. Bateman A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. *Trends Biochem Sci* 1997;**22**:12–3.
107. Scott JW, Hawley SA, Green KA, Anis M, Stewart G, Scullion GA, et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. *J Clin Invest* 2004;**113**:274–84.
108. Chen L, Wang J, Zhang YY, Yan SF, Neumann D, Schlattner U, et al. AMP-activated protein kinase undergoes nucleotide-dependent conformational changes. *Nat Struct Mol Biol* 2012;**19**:716–8.
109. Xin FJ, Wang J, Zhao RQ, Wang ZX, Wu JW. Coordinated regulation of AMPK activity by multiple elements in the α-subunit. *Cell Res* 2013;**23**:1237–40.
110. Riek U, Scholz R, Konarev P, Rufer A, Suter M, Nazabal A, et al. Structural properties of AMP-activated protein kinase: dimerization, molecular shape, and changes upon ligand binding. *J Biol Chem* 2008;**283**:18331–43.
111. Oakhill JS, Chen ZP, Scott JW, Steel R, Castelli LA, Ling NM, et al. β-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). *Proc Natl Acad Sci U S A* 2010;**107**:19237–41.
112. Leech A, Nath N, McCartney RR, Schmidt MC. Isolation of mutations in the catalytic domain of the SNF1 kinase that render its activity independent of the SNF4 subunit. *Eukaryot Cell* 2003;**2**:265–73.
113. Chandrashekarappa DG, McCartney RR, Schmidt MC. Ligand binding to the AMP-activated protein kinase active site mediates protection of the activation loop from dephosphorylation. *J Biol Chem* 2013;**288**:89–98.
114. Zhang CS, Jiang B, Li MQ, Zhu MJ, Peng YY, Zhang YL, et al. The lysosomal v-ATPase-regulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. *Cell Metab* 2014;**20**:526–40.
115. Zhang YL, Guo HL, Zhang CS, Lin SY, Yin ZY, Peng YY, et al. AMP as a low-energy charge signal autonomously initiates assembly of AXIN-AMPK-LKB1 complex for AMPK activation. *Cell Metab* 2013;**18**:546–55.
116. Horman S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A, et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase α-subunits in heart *via*

hierarchical phosphorylation of Ser485/491. *J Biol Chem* 2006;**281**:5335–40.
117. Hurley RL, Barré LK, Wood SD, Anderson KA, Kemp BE, Means AR, et al. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. *J Biol Chem* 2006;**281**:36662–72.
118. Djouder N, Tuerk RD, Suter M, Salvioni P, Thali RF, Scholz R, et al. PKA phosphorylates and inactivates AMPKα to promote efficient lipolysis. *EMBO J* 2010;**29**:469–81.
119. Suzuki T, Bridges D, Nakada D, Skiniotis G, Morrison SJ, Lin JD, et al. Inhibition of AMPK catabolic action by GSK3. *Mol Cell* 2013;**50**:407–19.
120. Serrill JD, Tan M, Fotso S, Sikorska J, Kasanah N, Hau AM, et al. Apoptolidins A and C activate AMPK in metabolically sensitive cell types and are mechanistically distinct from oligomycin A. *Biochem Pharmacol* 2015;**93**:251–65.
121. Tang X, Zhuang JJ, Chen J, Yu L, Hu LH, Jiang HL, et al. Arctigenin efficiently enhanced sedentary mice treadmill endurance. *PLoS One* 2011;**6**:e24224.
122. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. *Diabetes* 2006;**55**:2256–64.
123. Wu WD, Hu ZM, Shang MJ, Zhao DJ, Zhang CW, Hong DF, et al. Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signaling in GBC-SD gallbladder cancer cells. *Int J Mol Sci* 2014;**15**:12778–90.
124. Xiao N, Mei F, Sun Y, Pan GJ, Liu BL, Liu K. Quercetin, luteolin, and epigallocatechin gallate promote glucose disposal in adipocytes with regulation of AMP-activated kinase and/or sirtuin 1 activity. *Planta Med* 2014;**80**:993–1000.
125. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 2006;**444**:337–42.
126. Shrotriya S, Tyagi A, Deep G, Orlicky DJ, Wisell J, Wang XJ, et al. Grape seed extract and resveratrol prevent 4-nitroquinoline 1-oxide induced oral tumorigenesis in mice by modulating AMPK activation and associated biological responses. *Mol Carcinog* 2015;**54**:291–300.
127. Yeung ED, Morrison A, Plumeri D, Wang JY, Tong C, Yan XY, et al. Alternol exerts prostate-selective antitumor effects through modulations of the AMPK signaling pathway. *Prostate* 2012;**72**:165–72.
128. Hwang YP, Choi JH, Han EH, Kim HG, Wee JH, Jung KO, et al. Purple sweet potato anthocyanins attenuate hepatic lipid accumulation through activating adenosine monophosphate-activated protein kinase in human HepG2 cells and obese mice. *Nutr Res* 2011;**31**:896–906.
129. Ullah I, Park HY, Kim MO. Anthocyanins protect against kainic acid-induced excitotoxicity and apoptosis *via* ROS-activated AMPK pathway in hippocampal neurons. *CNS Neurosci Ther* 2014;**20**:327–38.
130. Ono M, Fujimori K. Antiadipogenic effect of dietary apigenin through activation of AMPK in 3T3-L1 cells. *J Agric Food Chem* 2011;**59**:13346–52.
131. Tan WQ, Chen G, Jia B, Ye M. Artemisinin inhibits neuroblastoma proliferation through activation of AHP-activated protein kinase (AMPK) signaling. *Pharmazie* 2014;**69**:468–72.
132. Son MJ, Minakawa M, Miura Y, Yagasaki K. Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic *ob/ob* mice. *Eur J Nutr* 2013;**52**:1607–19.
133. Dang Y, Ling S, Duan J, Ma J, Ni R, Xu JW. Bavachalcone-induced manganese superoxide dismutase expression through the AMP-activated protein kinase pathway in human endothelial cells. *Pharmacology* 2015;**95**:105–10.
134. Liao CC, Ou TT, Huang HP, Wang CJ. The inhibition of oleic acid induced hepatic lipogenesis and the promotion of lipolysis by caffeic acid *via* up-regulation of AMP-activated kinase. *J Sci Food Agric* 2014;**94**:1154–62.
135. Chiang EPI, Tsai SY, Kuo YH, Pai MH, Chiu HL, Rodriguez RL, et al. Caffeic acid derivatives inhibit the growth of colon cancer: involvement of the PI3-K/AKT and AMPK signaling pathways. *PLoS One* 2014;**9**:e99631.
136. Kim JH, Lee JO, Lee SK, Kim N, You GY, Moon JW, et al. Celastrol suppresses breast cancer MCF-7 cell viability *via* the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway. *Cell Signal* 2013;**25**:805–13.
137. Zhang TS, Yamamoto N, Ashida H. Chalcones suppress fatty acid-induced lipid accumulation through a LKB1/AMPK signaling pathway in HepG2 cells. *Food Funct* 2014;**5**:1134–41.
138. Chiu CY, Chan IL, Yang TH, Liu SH, Chiang MT. Supplementation of chitosan alleviates high-fat diet-enhanced lipogenesis in rats *via* adenosine monophosphate (AMP)-activated protein kinase activation and inhibition of lipogenesis-associated genes. *J Agric Food Chem* 2015;**63**:2979–88.
139. Shao JJ, Zhang AP, Qin W, Zheng L, Zhu YF, Chen X. AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells. *Biochem Biophys Res Commun* 2012;**423**:448–53.
140. Chen XB, Zhuang JJ, Liu JH, Lei M, Ma L, Chen J, et al. Potential AMPK activators of cucurbitane triterpenoids from *Siraitia grosvenorii* Swingle. *Bioorg Med Chem* 2011;**19**:5776–81.
141. Kubota M, Shimizu M, Sakai H, Yasuda Y, Terakura D, Baba A, et al. Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-*db/db* obese mice. *Nutr Cancer* 2012;**64**:72–9.
142. Jiménez-Flores LM, López-Briones S, Macías-Cervantes MH, Ramírez-Emiliano J, Pérez-Vázquez V. A PPARγ, NF-κB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic *db/db* mice liver. *Molecules* 2014;**19**:8289–302.
143. Park S, Kang S, Jeong DY, Jeong SY, Park JJ, Yun HS. Cyanidin and malvidin in aqueous extracts of black carrots fermented with Aspergillus oryzae prevent the impairment of energy, lipid and glucose metabolism in estrogen-deficient rats by AMPK activation. *Genes Nutr* 2015;**10**:455.
144. Kim SJ, Kim HM, Lee ES, Kim N, Lee JO, Lee HJ, et al. Dehydrozingerone exerts beneficial metabolic effects in high-fat diet-induced obese mice *via* AMPK activation in skeletal muscle. *J Cell Mol Med* 2015;**19**:620–9.
145. Jin X, Chen ML, Yi L, Chang H, Zhang T, Wang L, et al. Delphinidin-3-glucoside protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury by autophagy upregulation *via* the AMPK/SIRT1 signaling pathway. *Mol Nutr Food Res* 2014;**58**:1941–51.
146. Mandal S, Mukhopadhyay S, Bandhopadhyay S, Sen G, Biswas T. 14-Deoxyandrographolide alleviates ethanol-induced hepatosteatosis through stimulation of AMP-activated protein kinase activity in rats. *Alcohol* 2014;**48**:123–32.
147. Zhao ZQ, Yin JQ, Wu MS, Song GH, Xie XB, Zou CY, et al. Dihydromyricetin activates AMP-activated protein kinase and $P38^{MAPK}$ exerting antitumor potential in osteosarcoma. *Cancer Prev Res* 2014;**7**:927–38.
148. Ladurner A, Atanasov AG, Heiss EH, Baumgartner L, Schwaiger S, Rollinger JM, et al. 2-(2,4-Dihydroxyphenyl)-5-(*E*)-propenylbenzofuran promotes endothelial nitric oxide synthase activity in human endothelial cells. *Biochem Pharmacol* 2012;**84**:804–12.
149. Chen ZF, Zhang L, Yi JY, Yang ZB, Zhang ZJ, Li Z. Promotion of adiponectin multimerization by emodin: a novel AMPK activator with PPARγ-agonist activity. *J Cell Biochem* 2012;**113**:3547–58.
150. Tzeng TF, Lu HJ, Liou SS, Chang CJ, Liu IM. Emodin protects against high-fat diet-induced obesity *via* regulation of AMP-activated protein kinase pathways in white adipose tissue. *Planta Med* 2012;**78**:943–50.
151. Tzeng TF, Lu HJ, Liou SS, Chang CJ, Liu IM. Emodin, a naturally occurring anthraquinone derivative, ameliorates dyslipidemia by

activating AMP-activated protein kinase in high-fat-diet-fed rats. *Evid Based Complement Alternat Med* 2012;**2012**:781812.
152. Chen CC, Lin JT, Cheng YF, Kuo CY, Huang CF, Kao SH, et al. Amelioration of LPS-induced inflammation response in microglia by AMPK activation. *Biomed Res Int* 2014;**2014**:692061.
153. Huang BP, Lin CH, Chen HM, Lin JT, Cheng YF, Kao SH. AMPK activation inhibits expression of proinflammatory mediators through downregulation of PI3K/p38 MAPK and NF-κB signaling in murine macrophages. *DNA Cell Biol* 2015;**34**:133–41.
154. Chen D, Pamu S, Cui QZ, Chan TH, Dou QP. Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. *Bioorg Med Chem* 2012;**20**:3031–7.
155. Kuo YH, Lin CH, Shih CC. Ergostatrien-3β-ol from *Antrodia camphorata* inhibits diabetes and hyperlipidemia in high-fat-diet treated mice *via* regulation of hepatic related genes, glucose transporter 4, and AMP-activated protein kinase phosphorylation. *J Agric Food Chem* 2015;**63**:2479–89.
156. Jeong KJ, Kim DY, Quan HY, Jo HK, Kim GW, Chung SH. Effects of eugenol on hepatic glucose production and AMPK signaling pathway in hepatocytes and C57BL/6J mice. *Fitoterapia* 2014;**93**:150–62.
157. Lee YS, Cha BY, Choi SS, Harada Y, Choi BK, Yonezawa T, et al. Fargesin improves lipid and glucose metabolism in 3T3-L1 adipocytes and high-fat diet-induced obese mice. *Biofactors* 2012;**38**:300–8.
158. Seo JB, Park SW, Choe SS, Jeong HW, Park JY, Choi EW, et al. Foenumoside B from *Lysimachia foenum*-graecum inhibits adipocyte differentiation and obesity induced by high-fat diet. *Biochem Biophys Res Commun* 2012;**417**:800–6.
159. Kawaguchi T, Hayakawa M, Koga H, Torimura T. Effects of fucoidan on proliferation, AMP-activated protein kinase, and downstream metabolism- and cell cycle-associated molecules in poorly differentiated human hepatoma HLF cells. *Int J Oncol* 2015;**46**:2216–22.
160. Chen MH, Lin CH, Shih CC. Antidiabetic and antihyperlipidemic effects of *Clitocybe nuda* on glucose transporter 4 and AMP-activated protein kinase phosphorylation in high-fat-fed mice. *Evid Based Complement Alternat Med* 2014;**2014**:981046.
161. Shih CC, Chen MH, Lin CH. Validation of the antidiabetic and hypolipidemic effects of *Clitocybe nuda* by assessment of glucose transporter 4 and gluconeogenesis and AMPK phosphorylation in streptozotocin-induced mice. *Evid Based Complement Alternat Med* 2014;**2014**:705636.
162. Doan KV, Ko CM, Kinyua AW, Yang DJ, Choi YH, Oh IY, et al. Gallic acid regulates body weight and glucose homeostasis through AMPK activation. *Endocrinology* 2015;**156**:157–68.
163. Kim SH, Park EJ, Lee CR, Chun JN, Cho NH, Kim IG, et al. Geraniol induces cooperative interaction of apoptosis and autophagy to elicit cell death in PC-3 prostate cancer cells. *Int J Oncol* 2012;**40**:1683–90.
164. Shin SS, Park D, Lee HY, Hong Y, Choi J, Oh J, et al. The herbal composition GGEx18 from *Laminaria japonica*, *Rheum palmatum*, and *Ephedra sinica* reduces obesity *via* skeletal muscle AMPK and PPARα. *Pharm Biol* 2012;**50**:506–15.
165. Fan JZ, Yang X, Bi ZG. 6-Gingerol inhibits osteosarcoma cell proliferation through apoptosis and AMPK activation. *Tumour Biol* 2015;**36**:1135–41.
166. Lee JO, Kim N, Lee HJ, Moon JW, Lee SK, Kim SJ, et al. [6]-Gingerol affects glucose metabolism by dual regulation *via* the AMPKα2-mediated AS160-Rab5 pathway and AMPK-mediated insulin sensitizing effects. *J Cell Biochem* 2015;**116**:1401–10.
167. Li Y, Tran VH, Koolaji N, Duke C, Roufogalis BD. (*S*)-[6]-Gingerol enhances glucose uptake in L6 myotubes by activation of AMPK in response to $[Ca^{2+}]_i$. *J Pharm Pharm Sci* 2013;**16**:304–12.
168. Yuan HD, Kim do Y, Quan HY, Kim SJ, Jung MS, Chung SH. Ginsenoside Rg2 induces orphan nuclear receptor *SHP* gene expression and inactivates GSK3β *via* AMP-activated protein kinase to inhibit hepatic glucose production in HepG2 cells. *Chem Biol Interact* 2012;**195**:35–42.
169. Kim DY, Park YG, Quan HY, Kim SJ, Jung MS, Chung SH. Ginsenoside Rd stimulates the differentiation and mineralization of osteoblastic MC3T3-E1 cells by activating AMP-activated protein kinase *via* the BMP-2 signaling pathway. *Fitoterapia* 2012;**83**:215–22.
170. Quan HY, Yuan HD, Jung MS, Ko SK, Park YG, Chung SH. Ginsenoside Re lowers blood glucose and lipid levels *via* activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice. *Int J Mol Med* 2011;**29**:73–80.
171. Kim MJ, Yun H, Kim DH, Kang I, Choe W, Kim SS, et al. AMP-activated protein kinase determines apoptotic sensitivity of cancer cells to ginsenoside-Rh2. *J Ginseng Res* 2014;**38**:16–21.
172. Shin DJ, Kim JE, Lim TG, Jeong EH, Park G, Kang NJ, et al. 20-*O*-β-D-glucopyranosyl-20(*S*)-protopanaxadiol suppresses UV-induced MMP-1 expression through AMPK-mediated mTOR inhibition as a downstream of the PKA-LKB1 pathway. *J Cell Biochem* 2014;**115**:1702–11.
173. Lee JW, Choe SS, Jang H, Kim J, Jeong HW, Jo H, et al. AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity. *J Lipid Res* 2012;**53**:1277–86.
174. Sawada K, Yamashita Y, Zhang TS, Nakagawa K, Ashida H. Glabridin induces glucose uptake *via* the AMP-activated protein kinase pathway in muscle cells. *Mol Cell Endocrinol* 2014;**393**:99–108.
175. Banerjee S, Ghoshal S, Porter TD. Phosphorylation of hepatic AMP-activated protein kinase and liver kinase B1 is increased after a single oral dose of green tea extract to mice. *Nutr Res* 2012;**32**:985–90.
176. Huang HC, Lin JK. Pu-erh tea, green tea, and black tea suppresses hyperlipidemia, hyperleptinemia and fatty acid synthase through activating AMPK in rats fed a high-fructose diet. *Food Funct* 2012;**3**:170–7.
177. Lin YC, Hung CM, Tsai JC, Lee JC, Chen YLS, Wei CW, et al. Hispidulin potently inhibits human glioblastoma multiforme cells through activation of AMP-activated protein kinase (AMPK). *J Agric Food Chem* 2010;**58**:9511–7.
178. Yang JM, Hung CM, Fu CN, Lee JC, Huang CH, Yang MH, et al. Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation. *J Agric Food Chem* 2010;**58**:10020–6.
179. Wang YG, Liu WP, He XS, Fei Z. Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK. *Cell Biochem Biophys* 2015;**71**:701–6.
180. Kapoor S. Attenuation of tumor growth by honokiol: an evolving role in oncology. *Drug Discov Ther* 2012;**6**:327–8.
181. Seo MS, Kim JH, Kim HJ, Chang KC, Park SW. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes. *Toxicol Appl Pharmacol* 2015;**284**:113–24.
182. Yin JJ, Luo YQ, Deng HL, Qin SM, Tang WJ, Zeng L, et al. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells. *J Ethnopharmacol* 2014;**154**:229–39.
183. Yuan T, Nahar P, Sharma M, Liu K, Slitt A, Aisa HA, et al. Indazole-type alkaloids from *Nigella sativa* seeds exhibit antihyperglycemic effects *via* AMPK activation *in vitro*. *J Nat Prod* 2014;**77**:2316–20.
184. Zhou JX, Yoshitomi H, Liu TH, Zhou BX, Sun W, Qin LL, et al. Isoquercitrin activates the AMP-activated protein kinase (AMPK) signal pathway in rat H4IIE cells. *BMC Complement Altern Med* 2014;**14**:42.
185. Dong GZ, Lee JH, Ki SH, Yang JH, Cho IJ, Kang SH, et al. AMPK activation by isorhamnetin protects hepatocytes against oxidative stress and mitochondrial dysfunction. *Eur J Pharmacol* 2014;**740**:634–40.
186. Wang DK, Tian M, Qi Y, Chen G, Xu LJ, Zou X, et al. Jinlida granule inhibits palmitic acid induced-intracellular lipid accumulation and enhances autophagy in NIT-1 pancreatic β cells through AMPK activation. *J Ethnopharmacol* 2015;**161**:99–107.

187. Qian Q, Liu XF, He W, An YT, Chen Q, Wu JX, et al. TG accumulation inhibitory effects of Jinqi formula by AMPK signaling pathway. *J Ethnopharmacol* 2012;**143**:41–8.
188. Jaiswal N, Yadav PP, Maurya R, Srivastava AK, Tamrakar AK. Karanjin from *Pongamia pinnata* induces GLUT4 translocation in skeletal muscle cells in a phosphatidylinositol-3-kinase-independent manner. *Eur J Pharmacol* 2011;**670**:22–8.
189. Kim HS, Lim J, Lee da Y, Ryu JH, Lim JS. Kazinol C from *Broussonetia kazinoki* activates AMP-activated protein kinase to induce antitumorigenic effects in HT-29 colon cancer cells. *Oncol Rep* 2015;**33**:223–9.
190. Han JY, Park SH, Yang JH, Kim MG, Cho SS, Yoon G, et al. Licochalcone suppresses LXRα-induced hepatic lipogenic gene expression through AMPK/Sirt1 pathway activation. *Toxicol Res* 2014;**30**:19–25.
191. Jeong GS, Lee DS, Li B, Kim JJ, Kim EC, Kim YC. Anti-inflammatory effects of lindenenyl acetate *via* heme oxygenase-1 and AMPK in human periodontal ligament cells. *Eur J Pharmacol* 2011;**670**:295–303.
192. Niu YC, Li ST, Na LX, Feng RN, Liu LY, Li Y, et al. Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. *PLoS One* 2012;**7**:e30782.
193. Wan Y, Liu LY, Hong ZF, Peng J. Ethanol extract of *Cirsium japonicum* attenuates hepatic lipid accumulation *via* AMPK activation in human HepG2 cells. *Exp Ther Med* 2014;**8**:79–84.
194. Han J, Yi J, Liang FY, Jiang B, Xiao Y, Gao SH, et al. X-3, a mangiferin derivative, stimulates AMP-activated protein kinase and reduces hyperglycemia and obesity in *db/db* mice. *Mol Cell Endocrinol* 2015;**405**:63–73.
195. Song JN, Li J, Hou FJ, Wang XN, Liu BL. Mangiferin inhibits endoplasmic reticulum stress-associated thioredoxin-interacting protein/NLRP3 inflammasome activation with regulation of AMPK in endothelial cells. *Metabolism* 2015;**64**:428–37.
196. Chen YY, Lee MH, Hsu CC, Wei CL, Tsai YC. Methyl cinnamate inhibits adipocyte differentiation *via* activation of the CaMKK2-AMPK pathway in 3T3-L1 preadipocytes. *J Agric Food Chem* 2012;**60**:955–63.
197. Kim S, Ka SO, Lee Y, Park BH, Fei X, Jung JK, et al. The new 4-*O*-methylhonokiol analog GS12021 inhibits inflammation and macrophage chemotaxis: role of AMP-activated protein kinase α activation. *PLoS One* 2015;**10**:e0117120.
198. Ptitsyn LR, Nomura K, Sklyar IV K, Ravcheeva AB. The 1,4-naphthoquinone derivative from *Pyrola rotundifolia* activates AMPK phosphorylation in C2C12 myotubes. *Fitoterapia* 2011;**82**:1285–9.
199. Hsu WH, Chen TH, Lee BH, Hsu YW, Pan TM. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice. *Food Chem Toxicol* 2014;**64**:94–103.
200. Chen RJ, Hung CM, Chen YL, Wu MD, Yuan GF, Wang YJ. Monascuspiloin induces apoptosis and autophagic cell death in human prostate cancer cells *via* the AKT and AMPK signaling pathways. *J Agric Food Chem* 2012;**60**:7185–93.
201. Pu P, Gao DM, Mohamed S, Chen J, Zhang J, Zhou XY, et al. Naringin ameliorates metabolic syndrome by activating AMP-activated protein kinase in mice fed a high-fat diet. *Arch Biochem Biophys* 2012;**518**:61–70.
202. Hien TT, Ki SH, Yang JW, Oh WK, Kang KW. Nectandrin B suppresses the expression of adhesion molecules in endothelial cells: role of AMP-activated protein kinase activation. *Food Chem Toxicol* 2014;**66**:286–94.
203. Hien TT, Oh WK, Nguyen PH, Oh SJ, Lee MY, Kang KW. Nectandrin B activates endothelial nitric-oxide synthase phosphorylation in endothelial cells: role of the AMP-activated protein kinase/estrogen receptor α/phosphatidylinositol 3-kinase/AKT pathway. *Mol Pharmacol* 2011;**80**:1166–78.
204. Ki SH, Lee JW, Lim SC, Hien TT, Im JH, Oh WK, et al. Protective effect of nectandrin B, a potent AMPK activator on neointima formation: inhibition of Pin1 expression through AMPK activation. *Br J Pharmacol* 2013;**168**:932–45.
205. Lee SH, Kang SM, Ko SC, Lee DH, Jeon YJ. Octaphlorethol A, a novel phenolic compound isolated from a brown alga, *Ishige foliacea*, increases glucose transporter 4-mediated glucose uptake in skeletal muscle cells. *Biochem Biophys Res Commun* 2012;**420**:576–81.
206. Liu J, Zheng LH, Wu N, Ma LN, Zhong JT, Liu G, et al. Oleanolic acid induces metabolic adaptation in cancer cells by activating the AMP-activated protein kinase pathway. *J Agric Food Chem* 2014;**62**:5528–37.
207. Lee WH, Lin RJ, Lin SY, Chen YC, Lin HM, Liang YC. Osthole enhances glucose uptake through activation of AMP-activated protein kinase in skeletal muscle cells. *J Agric Food Chem* 2011;**59**:12874–81.
208. Lee WH, Wu HH, Huang WJ, Li YN, Lin RJ, Lin SY, et al. *N*-hydroxycinnamide derivatives of osthole ameliorate hyperglycemia through activation of AMPK and p38 MAPK. *Molecules* 2015;**20**:4516–29.
209. Lu C, Wang WW, Jia YS, Liu XD, Tong ZS, Li BH. Inhibition of AMPK/autophagy potentiates parthenolide-induced apoptosis in human breast cancer cells. *J Cell Biochem* 2014;**115**:1458–66.
210. Zou B, Ge ZZ, Zhang Y, Du J, Xu Z, Li CM. Persimmon tannin accounts for hypolipidemic effects of persimmon through activating of AMPK and suppressing NF-κB activation and inflammatory responses in high-fat diet rats. *Food Funct* 2014;**5**:1536–46.
211. Adachi Y, Kanbayashi Y, Harata I, Ubagai R, Takimoto T, Suzuki K, et al. Petasin activates AMP-activated protein kinase and modulates glucose metabolism. *J Nat Prod* 2014;**77**:1262–9.
212. Ryu J, Kim MJ, Kim TO, Huh TL, Lee SE. Piperlongumine as a potential activator of AMP-activated protein kinase in HepG2 cells. *Nat Prod Res* 2014;**28**:2040–3.
213. Kim DY, Kim MS, Sa BK, Kim MB, Hwang JK. *Boesenbergia pandurata* attenuates diet-induced obesity by activating AMP-activated protein kinase and regulating lipid metabolism. *Int J Mol Sci* 2012;**13**:994–1005.
214. Kang H, Koppula S. *Houttuynia cordata* attenuates lipid accumulation *via* activation of AMP-activated protein kinase signaling pathway in HepG2 cells. *Am J Chin Med* 2014;**42**:651–64.
215. Shin JA, Kwon KH, Cho SD. AMPK-activated protein kinase activation by *Impatiens balsamina* L. is related to apoptosis in HSC-2 human oral cancer cells. *Pharmacogn Mag* 2015;**11**:136–42.
216. Li W, Li Y, Wang Q, Yang Y. Crude extracts from *Lycium barbarum* suppress SREBP-1c expression and prevent diet-induced fatty liver through AMPK activation. *Biomed Res Int* 2014;**2014**:196198.
217. Jeong YT, Song CH. Antidiabetic activities of extract from *Malva verticillata* seed *via* the activation of AMP-activated protein kinase. *J Microbiol Biotechnol* 2011;**21**:921–9.
218. Kim A, Im M, Ma JY. Ethanol extract of *Remotiflori* radix induces endoplasmic reticulum stress-mediated cell death through AMPK/mTOR signaling in human prostate cancer cells. *Sci Rep* 2015;**5**:8394.
219. Lee JO, Moon JW, Lee SK, Kim SM, Kim N, Ko SG, et al. *Rhus verniciflua* extract modulates survival of MCF-7 breast cancer cells through the modulation of AMPK-pathway. *Biol Pharm Bull* 2014;**37**:794–801.
220. Song KH, Lee SH, Kim BY, Park AY, Kim JY. Extracts of *Scutellaria baicalensis* reduced body weight and blood triglyceride in *db/db* mice. *Phytother Res* 2013;**27**:244–50.
221. Wu CH, Ou TT, Chang CH, Chang XZ, Yang MY, Wang CJ. The polyphenol extract from *Sechium edule* shoots inhibits lipogenesis and stimulates lipolysis *via* activation of AMPK signals in HepG2 cells. *J Agric Food Chem* 2014;**62**:750–9.
222. Liu YJ, Shieh PC, Lee JC, Chen FA, Lee CH, Kuo SC, et al. Hypolipidemic activity of *Taraxacum mongolicum* associated with the activation of AMP-activated protein kinase in human HepG2 cells. *Food Funct* 2014;**5**:1755–62.
223. Papadimitriou A, EBMI Peixoto, Silva KC, Lopes de Faria JM, Lopes de Faria JB. Increase in AMPK brought about by cocoa is

renoprotective in experimental diabetes mellitus by reducing NOX4/TGFβ-1 signaling. *J Nutr Biochem* 2014;**25**:773–84.
224. Sung YY, Kim DS, Kim HK. *Viola mandshurica* ethanolic extract prevents high-fat-diet-induced obesity in mice by activating AMP-activated protein kinase. *Environ Toxicol Pharmacol* 2014;**38**:41–50.
225. Pan CH, Tsai CH, Lin WH, Chen GY, Wu CH. Ethanolic extract of *Vitis thunbergii* exhibits lipid lowering properties *via* modulation of the AMPK-ACC pathway in hypercholesterolemic rabbits. *Evid Based Complement Alternat Med* 2012;**2012**:436786.
226. Youn SH, Lee JS, Lee MS, Cha EY, Thuong PT, Kim JR, et al. Anticancer properties of pomolic acid-induced AMP-activated protein kinase activation in MCF7 human breast cancer cells. *Biol Pharm Bull* 2012;**35**:105–10.
227. Lin VCH, Tsai YC, Lin JN, Fan LL, Pan MH, Ho CT, et al. Activation of AMPK by pterostilbene suppresses lipogenesis and cell-cycle progression in p53 positive and negative human prostate cancer cells. *J Agric Food Chem* 2012;**60**:6399–407.
228. Kang OH, Kim SB, Mun SH, Seo YS, Hwang HC, Lee YM, et al. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes. *Int J Mol Med* 2015;**35**:803–9.
229. Thyagarajan-Sahu A, Lane B, Sliva D. ReishiMax, mushroom based dietary supplement, inhibits adipocyte differentiation, stimulates glucose uptake and activates AMPK. *BMC Complement Altern Med* 2011;**11**:74.
230. Khanal P, Kang BS, Yun HJ, Cho HG, Makarieva TN, Choi HS. Aglycon of rhizochalin from the *Rhizochalina incrustata* induces apoptosis *via* activation of AMP-activated protein kinase in HT-29 colon cancer cells. *Biol Pharm Bull* 2011;**34**:1553–8.
231. Lee NY, Park KY, Min HJ, Song KY, Lim YY, Park J, et al. Inhibitory effect of vitamin U (*S*-methylmethionine sulfonium chloride) on differentiation in 3T3-L1 pre-adipocyte cell lines. *Ann Dermatol* 2012;**24**:39–44.
232. Liu ZB, Li XS, Simoneau AR, Jafari M, Zi XL. *Rhodiola rosea* extracts and salidroside decrease the growth of bladder cancer cell lines *via* inhibition of the mTOR pathway and induction of autophagy. *Mol Carcinog* 2012;**51**:257–67.
233. Ge YQ, Xu XF, Yang B, Chen Z, Cheng RB. Saponins from *Rubus parvifolius* L. induce apoptosis in human chronic myeloid leukemia cells through AMPK activation and STAT3 inhibition. *Asian Pac J Cancer Prev* 2014;**15**:5455–61.
234. Lee HI, Yun KW, Seo KI, Kim MJ, Lee MK. Scopoletin prevents alcohol-induced hepatic lipid accumulation by modulating the AMPK-SREBP pathway in diet-induced obese mice. *Metabolism* 2014;**63**:593–601.
235. Roblet C, Doyen A, Amiot J, Pilon G, Marette A, Bazinet L. Enhancement of glucose uptake in muscular cell by soybean charged peptides isolated by electrodialysis with ultrafiltration membranes (EDUF): activation of the AMPK pathway. *Food Chem* 2014;**147**:124–30.
236. Choi KM, Lee YS, Kim W, Kim SJ, Shin KO, Yu JY, et al. Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice. *J Nutr Biochem* 2014;**25**:201–7.
237. Kim MS, Hur HJ, Kwon DY, Hwang JT. Tangeretin stimulates glucose uptake *via* regulation of AMPK signaling pathways in C2C12 myotubes and improves glucose tolerance in high-fat diet-induced obese mice. *Mol Cell Endocrinol* 2012;**358**:127–34.
238. Hwang SL, Yang JH, Jeong YT, Kim YD, Li X, Lu Y, et al. Tanshinone IIA improves endoplasmic reticulum stress-induced insulin resistance through AMP-activated protein kinase. *Biochem Biophys Res Commun* 2013;**430**:1246–52.
239. Wu WY, Yan H, Wang XB, Gui YZ, Gao F, Tang XL, et al. Sodium tanshinone IIA silate inhibits high glucose-induced vascular smooth muscle cell proliferation and migration through activation of AMP-activated protein kinase. *PLoS One* 2014;**9**:e94957.
240. Park HY, Kunitake Y, Hirasaki N, Tanaka M, Matsui T. Theaflavins enhance intestinal barrier of Caco-2 Cell monolayers through the expression of AMP-activated protein kinase-mediated Occludin, Claudin-1, and ZO-1. *Biosci Biotechnol Biochem* 2015;**79**:130–7.
241. Qiu J, Maekawa K, Kitamura Y, Miyata Y, Tanaka K, Tanaka T, et al. Stimulation of glucose uptake by theasinensins through the AMP-activated protein kinase pathway in rat skeletal muscle cells. *Biochem Pharmacol* 2014;**87**:344–51.
242. Bai T, Yang Y, Wu YL, Jiang S, Lee JJ, Lian LH, et al. Thymoquinone alleviates thioacetamide-induced hepatic fibrosis and inflammation by activating LKB1-AMPK signaling pathway in mice. *Int Immunopharmacol* 2014;**19**:351–7.
243. Goto T, Teraminami A, Lee JY, Ohyama K, Funakoshi K, Kim YI, et al. Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders *via* activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice. *J Nutr Biochem* 2012;**23**:768–76.
244. Wu JB, Kuo YH, Lin CH, Ho HY, Shih CC. Tormentic acid, a major component of suspension cells of *Eriobotrya japonica*, suppresses high-fat diet-induced diabetes and hyperlipidemia by glucose transporter 4 and AMP-activated protein kinase phosphorylation. *J Agric Food Chem* 2014;**62**:10717–26.
245. Kopp C, Singh SP, Regenhard P, Müller U, Sauerwein H, Mielenz M. *Trans*-cinnamic acid increases adiponectin and the phosphorylation of AMP-activated protein kinase through G-protein-coupled receptor signaling in 3T3-L1 adipocytes. *Int J Mol Sci* 2014;**15**:2906–15.
246. Hu X, Wang S, Xu J, Wang DB, Chen Y, Yang GZ. Triterpenoid saponins from *Stauntonia chinensis* ameliorate insulin resistance *via* the AMP-activated protein kinase and IR/IRS-1/PI3K/AKT pathways in insulin-resistant HepG2 cells. *Int J Mol Sci* 2014;**15**:10446–58.
247. Zheng QY, Jin FS, Yao C, Zhang T, Zhang GH, Ai X. Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. *Biochem Biophys Res Commun* 2012;**419**:741–7.
248. Yang YB, Zhao ZX, Liu YJ, Kang XJ, Zhang HS, Meng M. Suppression of oxidative stress and improvement of liver functions in mice by ursolic acid *via* LKB1-AMP-activated protein kinase signaling. *J Gastroenterol Hepatol* 2015;**30**:609–18.
249. Lai CS, Tsai ML, Badmaev V, Jimenez M, Ho CT, Pan MH. Xanthigen suppresses preadipocyte differentiation and adipogenesis through down-regulation of PPARγ and C/EBPs and modulation of SIRT-1, AMPK, and FoxO pathways. *J Agric Food Chem* 2012;**60**:1094–101.
250. Romero-Pérez AI, Lamuela-Raventós RM, Andrés-Lacueva C, de La Torre-Boronat MC. Method for the quantitative extraction of resveratrol and piceid isomers in grape berry skins. Effect of powdery mildew on the stilbene content. *J Agric Food Chem* 2001;**49**:210–5.
251. Rencurel F, Foretz M, Kaufmann MR, Stroka D, Looser R, Leclerc I, et al. Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. *Mol Pharmacol* 2006;**70**:1925–34.
252. Rencurel F, Stenhouse A, Hawley SA, Friedberg T, Hardie DG, Sutherland C, et al. AMP-activated protein kinase mediates phenobarbital induction of *CYP2B* gene expression in hepatocytes and a newly derived human hepatoma cell line. *J Biol Chem* 2005;**280**:4367–4373.